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ABSTRACT 
 
 
BACKGROUND: Super-utilizers are individuals with disproportionately high inpatient 
and emergency department (ED) use, and mostly have multiple chronic conditions and 
use multiple concurrent medications. They place a substantial burden on the U.S. 
healthcare system and have become the focus of policy initiatives aimed at reducing their 
disproportionate inpatient and ED use. Medication management is critical for these 
patients since nonadherence to essential chronic medications is associated with poor 
health outcomes, and higher health care utilization and costs. 
 
OBJECTIVES: This dissertation employed a three empirical research papers approach 
to study the following aims: (1) the prevalence and patterns of medication nonadherence 
to essential chronic medications in Medicare super-utilizers with chronic conditions, and 
to identify the factors associated with medication nonadherence, with special emphasis on 
factors including mental illness and use of opioid medications, (2) examine associations 
between medication nonadherence, and inpatient and ED use, and to evaluate other risk 
factors associated with health care utilization in Medicare super-utilizers with chronic 
conditions, and (3) examine the impact of the SafeMed Program, a care transitions 
program with a focus on medication management, on medication use and adherence 
among publicly insured super-utilizers with chronic conditions. 
 
METHODS: This dissertation was based on patients eligible for the SafeMed Program, a 
care transitions program with a focus on medication management. The SafeMed Program 
targeted publicly insured super-utilizers with chronic conditions who were admitted to 
three hospitals that were part of a non-profit hospital system in Memphis, TN. The study 
sample included Medicare or TennCare insured adults who met the SafeMed Program 
eligibility criteria, had continuous medication coverage, and filled at least one of the drug 
classes used to treat hypertension, congestive heart failure, coronary artery disease, 
diabetes mellitus, chronic obstructive pulmonary disease (COPD), or asthma. Papers 1 
and 2 were retrospective panel data analyses of the 2-year baseline data for Medicare Part 
D beneficiaries meeting the SafeMed Program eligibility criteria. Association between 
various factors and medication nonadherence was examined using random effects models 
with a binary distribution. Association between medication nonadherence and inpatient 
and ED utilization was examined using fixed effects negative binomial analyses. Paper 3 
used a prospective quasi-experimental study design to examine the effectiveness of the 
SafeMed Program on medication use and adherence among SafeMed participants 
compared with patients in a control group using a difference in differences (DID) 
approach.  
 
RESULTS: Paper 1 demonstrated that the proportion of patients who were nonadherent 
to their essential chronic disease medications ranged from 45.7% to 58.4%, with the 
highest rate for COPD/Asthma medications (54.3% to 64.4%). In the multivariate 
analysis examining predictors of medication nonadherence, we found that compared with 
patients who did not use any opioid medication in the previous period, patients using >4 
opioid medications had higher odds of medication nonadherence. Other risk factors for 
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nonadherence included age <65 years, dual beneficiaries receiving low income subsidy, 
and higher number of unique prescribers. Factors associated with lower odds of 
nonadherence included number of different medications filled and >1 physician office 
visits in the previous period.  
 
When examining the associations between medication nonadherence, and inpatient and 
ED use in Paper 2, we found that among elderly Medicare beneficiaries, nonadherence 
was significantly associated with a 57% increase in inpatient hospitalizations, and among 
non-elderly Medicare beneficiaries, nonadherence was significantly associated with 41% 
increase in inpatient stays and 25% increase in ED visits. Similar associations were found 
across all therapy classes examined (diabetes, cardiovascular, and COPD/asthma) in both 
age groups. However, nonadherence to diabetes and COPD/asthma drugs was not 
significantly associated with ED visits. Among other factors, mental illness, substance 
use disorder, non-Hispanic blacks and dual low-income subsidy status were associated 
with higher inpatient and ED use. 
 
Finally, the DID analyses in paper 3 showed that SafeMed Program did not improve 
medication adherence in vulnerable super-utilizers with chronic conditions. However, for 
some sub-group populations including Medicare only beneficiaries, patients >65 years of 
age, and patients with lower number of comorbidities, the intervention may have ensured 
that the decline in the probability of being adherent was not as low as it would have been 
in the absence of the intervention. Additionally, for patients diagnosed with 
COPD/asthma and diabetes, there were positive medication use trends in favor of 
enrollees, however, these associations were not statistically significant. 
 
CONCLUSIONS: This study is the first to our knowledge to demonstrate the magnitude 
and importance of medication nonadherence in vulnerable super-utilizers with chronic 
conditions. The study findings show that medication nonadherence is a significant 
problem among super-utilizers with chronic conditions and is associated with high 
inpatient and ED utilization. Furthermore, the findings suggest that medication 
management interventions during care transitions may not be sufficient for these high-
risk patients and other alternative strategies such as addressing social risk factors, and 
removing cost barriers may be needed to improve adherence, especially among low-
income dual beneficiaries, Medicaid enrollees, and patients with higher comorbidity. 
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CHAPTER 1.    INTRODUCTION 
 
 
MEDICATION ADHERENCE 
 
Medication adherence has been defined as the active, voluntary, and collaborative 
involvement of the patient in a mutually acceptable course of behavior to produce a 
therapeutic result.1 It usually refers to the extent to which patients take medications as 
prescribed by their health care provider.2 This form of patient behavior comprises of two 
main concepts—adherence and persistence. Adherence refers to the intensity of the 
therapy, whereas persistence refers to the overall duration of the therapy.1 Consistent and 
long-term use of essential chronic disease medications is critical for the treatment of 
chronic conditions such as diabetes, hypertension, cardiovascular disease (CVD), and 
chronic lung disease. Nonadherence to essential medications is a major barrier to 
achieving optimal therapeutic goals and is associated with poor clinical outcomes, and 
higher health care utilization and costs.3-6 Studies have shown that poor adherence to 
pharmacotherapy contributes to 33% to 69% of all medication-related hospitalizations 
and leads to expenses of approximately $100 billion a year.7 Given the magnitude and 
importance of medication adherence, assessing adherence has become an essential 
component for clinical trials. Additionally, the National Committee for Quality 
Assurance and Centers for Medicare and Medicaid Services (CMS) have included 
medication adherence as a quality measure to evaluate healthcare plans.8 
 
Medication nonadherence is a significant problem during the vulnerable period of 
care transitions, especially among patients with multiple chronic conditions (MCC) and 
complex medication regimen.9,10 There are two forms of nonadherence that may occur, 
primary nonadherence and secondary nonadherence. Primary nonadherence is defined as 
patient’s delay or failure to fill a new prescription, while secondary nonadherence—a 
more widely studied phenomenon—is defined as filling a prescription but not taking it as 
directed by the physicians.11 Research has shown that nearly 22% of prescription 
medications are never filled11 and approximately 50% of all prescription medications for 
chronic disease are not taken as directed by the provider.12 In the past, assessing primary 
nonadherence was difficult because it required cumbersome review of office notes and 
paper prescriptions. However, the recent increase in electronic prescribing systems has 
enabled researchers to assess primary nonadherence by linking patient’s prescription data 
with the pharmacy fill data. Secondary nonadherence, on the other hand, has been widely 
studied by researchers and can be captured by most of the adherence measures including 
patient-reported questionnaires or pharmacy administrative claims data. Studies 
examining primary and secondary nonadherence after hospital discharge have mainly 
focused on new medication users or patients who received new prescriptions during 
hospital discharge. 
 
A substantial body of evidence suggests that patients belonging to low 
socioeconomic strata are particularly at a higher risk for primary nonadherence.11,13,14 
Fisher and colleagues found that patients residing in low-income ZIP code areas were 
more likely to not fill their new prescriptions.11 Additionally, in our previous study we 
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found that more than 50% of vulnerable patients with MCC and polypharmacy (taking 
multiple medications concurrently for disease management), and those residing in 
medically underserved area, did not have all essential chronic and acute medications 
within three days of hospital discharge.13 In another study by Kripalani and colleagues, 
who evaluated medication reconciliation problems among inner-city patients after 
hospital discharge, found that only 40% patients filled their medications on the day of 
their discharge, 20% filled them within 1-2 days, 18% waited for 3-9 days, and 22% did 
not fill them until 12 days after discharge.14 These studies highlight the importance of 
examining primary nonadherence to essential chronic and acute medications in 
vulnerable low-income populations and addressing any financial barriers which may be 
playing a role in their non-adherent behavior. 
 
Studies examining secondary nonadherence have found that the rates of adherence 
drop progressively after hospital discharge. Newby and colleagues found that only 21% 
of patients with coronary artery disease were adherent to all essential cardiovascular 
medications over a 6-month period after hospital discharge.15 Ho and colleagues found 
that among patients discharged with aspirin, β-blockers, and statins, nearly 34% of 
patients stopped taking at least one medication and 12% stopped taking all three 
medications within one month of discharge.16 Along with the issue of medication 
nonadherence, vulnerable patients with MCC and those experiencing frequent transitions 
of care are at far greater risk for drug therapy problems and adverse drug events (ADE). 
Following hospital discharge, nearly 81% of the hospitalized patients experience drug 
therapy problems,13 14% to 75% of patients experience medication discrepancies,13,17,18 
and 11% to 30% of patients experience ADE of which about half are considered 
preventable or ameliorable.19,20 Taken together, these study findings suggest that 
medication management is critical during the vulnerable period of care transitions, 
especially among patients who are at risk of drug therapy problems and medication 
nonadherence. 
 
 
Methods to Measure Adherence 
 
There are several ways to measure adherence, which have been broadly classified 
as direct and indirect measures of adherence. Direct methods include directly observed 
therapy, measuring drug or metabolite concentration in body fluids, or measuring of 
biological markers in the blood that has been added to the drug formulation. Indirect 
measures of adherence include patient questionnaires and self-reports, pill counts, rates of 
prescription refills, electronic medication monitors, measuring physiologic markers, and 
asking patients to maintain diaries. The advantage of using direct methods is that it is 
possible to assess directly whether the patient has consumed medications or not, or 
whether the correct dose of medication has been taken or not. With indirect methods that 
assess adherence using patient responses or analyzing their pharmacy claims data, it is 
not possible to know whether the patient adheres to the agreed upon dosage and timing of 
the medication regimen. The choice of the adherence measure depends on the availability 
of the data and cost. Although direct methods have been considered more reliable and 
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accurate than indirect methods, these methods are expensive, tedious, and not practical 
for routine clinical use.7,21 
 
Among indirect methods, patient questionnaires such as Morisky medication 
adherence scale has been used in many studies and has produced reliable results for 
patients with hypertension and diabetes;22 however, the accuracy and validity of this 
method remains uncertain in patients with multiple chronic conditions using multiple 
concurrent medications.13 Adherence to Refills and Medication Scale (ARMS) is another 
patient-reported measure that can be used for chronic disease population and is a reliable 
medication adherence scale for patients with low literacy.23 However, the drawback of 
using most patient-reported adherence measures is that they provide a subjective way to 
measure adherence and patients may obfuscate and provide desired answers, and also 
subject to recall bias. Additionally, patient-reported adherence measures are susceptible 
to misrepresentation by the person collecting the data. Measuring adherence using 
pharmacy administrative data has gained importance recently and has become one of the 
most commonly used methods in the literature. Availability of pharmacy administrative 
data has enhanced our ability to measure adherence by understanding patients’ 
prescription refill patterns and behaviors that are necessary to achieve desirable treatment 
outcomes. Moreover, this method provides an objective method to assess adherence. 
Using this method, most observational studies and randomized clinical trials use a 
standard cut-off value of 80% and classify patients as adherent if they have medications 
on hand available for at least 80% of the total duration of time.1 Moreover, studies have 
established the clinical significance of defining the optimal adherence threshold of 80% 
or above.1,7 
 
Rates of refilling prescriptions is an accurate method to measure adherence in a 
closed pharmacy system (e.g., continuous Medicare Part D enrollment). However, the 
disadvantages of using this method are that it cannot capture primary nonadherence and 
may not accurately capture medication use beyond the medication fill. Additionally, 
pharmacy administrative claims data is widely used to assess adherence for a single drug 
class. However, measuring adherence for patients with MCC is difficult since patients use 
multiple concurrent medications. Choudhry and colleagues conducted a study to propose 
methods for measuring adherence to multiple medications.21 The study found variations 
in adherent rates depending on the way adherence was defined. And the study concluded 
that the choice of method depends on the reason why adherence is being measured. The 
interval-based proportion of days covered (PDC) is one of the standardized methods 
proposed in this study to measure adherence to concurrent medications. The interval-
based PDC is defined as medication possession during the interval from the index date to 
the end of the period, that is, number of days of medication supplied throughout the 
period (numerator) divided by number of days in the period (denominator). This method 
can be applied in following three distinct ways: 1) measuring average PDC for each 
patient based on the number of drug classes used by the patient, 2) measuring number of 
days during the period in which patients had at least one of the prescribed medications for 
a chronic condition, and 3) examining whether patients had a PDC of 80% or more for 
each medication they were using for a chronic condition. Different methods produce 
varying adherence estimates, and measuring average PDC (method #1) seems more 
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reliable since it produces intermediate adherence estimates when compared with the other 
two methods. Requiring patients to have a PDC of >80% for all medications may 
categories more patients as nonadherent, while requiring patients to be adherent to at least 
one or their medications may categorize more patients are adherent.21 
 
 
Barriers to Medication Adherence 
 
Barriers to medication adherence are multifactorial. The World Health 
Organization (WHO) has classified barriers to medication adherence into five broad 
categories: 1) patient-related factors, 2) patient conditions, 3) therapy related factors, 4) 
socioeconomic factors, and 5) health system related factors.1 Patient factors include age, 
gender, and race and ethnicity (minority race in particular). Patient conditions that are 
chronic in nature and require long-term therapy have been found to be associated with 
nonadherence. For therapy-related factors, patients having polypharmacy and complex 
therapy or patients experiencing side effects are more likely to have poor adherence. 
Among socioeconomic factors, lower education level, low income, and low health 
literacy are major barriers. Health system factors also play an important role in 
medication nonadherence. Some of the health care system-related barriers include having 
high cost of medications, copays, restricted formularies, or switching to another 
formulary.  
 
Review of existing literature demonstrates that the most important factors 
associated with medication nonadherence include young age, black race, medication 
copay, mental illness, multiple comorbidities, and therapy complexity, among others.3,7,24-
29 System-level factors such as inadequate post-discharge treatment plan, lack of patient 
counseling, discharge summaries lacking discharge medications, and failure to monitor 
patient’s drug therapy are associated with nonadherence and other drug therapy problems 
during care transitions.18-20,30-34 Makaryus and colleagues found that less than 50% of 
patients were able to list their discharge medications and even fewer could recount their 
purpose.35 In our previous study, we found that drug therapy problems and post-discharge 
medication discrepancies were common among super-utilizing patients with MCC and 
polypharmacy. The major causes of medication discrepancies were higher number of 
comorbidities, difficulty in picking up and paying for medications, and transportation.13 
Additionally, Kripalani and colleagues found that medication costs and transportation 
served as major barriers to proper medication use after hospital discharge among inner-
city patients.14 A comprehensive patient-centered approach addressing contributors to 
medication nonadherence and other drug therapy problems both at the patient- and 
system-level is needed to target effective interventions for vulnerable populations. 
 
 
Association of Adherence with Health Outcomes and Costs 
 
 Studies have demonstrated the positive impact of appropriate adherence on 
clinical outcomes. For instance, Bailey and colleagues found that among TennCare 
beneficiaries, a 15% increase in antihypertensive medication refill adherence was 
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associated with an 8% decreased hazard of stroke and a 7% decreased hazards of death.3 
Ho and colleagues conducted a retrospective cohort study of patients with diabetes and 
found that nonadherent patients had significantly increased risk for all-cause 
hospitalization and all-cause mortality.36 Another observational study by Ho and 
colleagues among a cohort of patients with coronary artery disease showed that 
nonadherence to cardioprotective medications (beta blockers, statins, and/or angiotensin-
converting enzyme inhibitors) was associated with increased risks for cardiovascular 
mortality and cardiovascular hospitalization.37 
 
Studies have also demonstrated the impact of medication adherence on health care 
utilization and costs. Sokol and colleagues analyzed a cohort of patients with four chronic 
conditions (diabetes, hypertension, hypercholesterolemia, and congestive heart failure) 
and found that high medication adherence was significantly associated with lower 
hospitalization and lower non-medication medical costs, yielding a net reduction in the 
overall healthcare costs.38 Roebuck and colleagues evaluated patients with congestive 
heart failure, hypertension, diabetes, and dyslipidemia and found that although improved 
medication adherence increased pharmacy costs, it also produced substantial medical 
savings by reducing hospitalizations and emergency department (ED) use.5 Jha and 
colleagues examined a national sample of diabetes patients and found that improved 
adherence to diabetes medications was associated with lower hospitalization and ED 
visits. Furthermore, the study projected that improved adherence to diabetes medications 
could avert 699,000 ED visits and 341,000 hospitalizations annually, generating savings 
of $4.7 billion.4 Similar findings were observed by studies conducted on Medicare 
beneficiaries. Simoni-Wastila and colleagues found that Medicare patients with chronic 
obstructive pulmonary disease (COPD) who were adherent to their chronic medications 
experienced fewer hospitalizations.6 And in a sample of Medicare patients with 
myocardial infarction, Zhang and colleagues found that higher adherence with β-
blockers, statins, and ACEIs/ARBs medications was associated with lower readmission 
rates.39 Findings from these studies reinforce the importance of taking medications as 
prescribed by the provider to optimize patient health outcomes and reduce health care 
utilization and costs. Previous studies based on Medicare population examining the 
association between medication adherence and utilization were largely represented by 
elderly Medicare beneficiaries and did not target vulnerable patients with high rates of 
multimorbidity and high health care utilization. 
 
 
Interventions to Improve Adherence 
 
Multimodal interventions focusing on multiple barriers of medication adherence 
have mostly shown improvements in medication adherence and reduced health care 
utilization. For instance, the Ashville projects that combined expanded medication 
therapy management (MTM) and disease management services, showed improved 
clinical outcomes and reduced overall costs in studies targeting commercially insured 
patients with diabetes, hypertension/dyslipidemia, or asthma.40-42 Similarly, Pringle and 
colleagues evaluated the impact of a large-scale, pharmacy-based intervention on five 
chronic medication classes and found that, compared to the control group, the 
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intervention group had improved adherence for all medication classes.43 Zillich and 
colleagues evaluated the effect of a program combining specialized medication packaging 
and phone MTM on medication adherence, health care utilization, and costs, among 
Medicaid patients. The study findings showed a significant improvement in medication 
adherence in the program cohort compared to controls; however, the effect on health care 
utilization and health care costs did not vary between the two groups.44 Additionally, 
Martin and colleagues examined the effectiveness of community-based, multimedia 
interventions on medication adherence among low-income rural residents with 
hypertension and found that medication adherence did not differ significantly from 
individuals in the control group.45 
 
 
INTEREST AND EVIDENCE IN CARE TRANSITIONS 
 
Care transitions is described as a process when patient’s care shifts from being 
provided in one setting to another, for instance moving from a hospital to a patient’s 
home.46 Patients with complex care needs often require care at different settings. During 
care transitions, these patients often experience difficulties in managing their care and 
face problems of care fragmentation. Managing care transitions is important since 
inadequate management contributes to $25 to $45 billion in wasteful spending mainly 
through avoidable complications and unnecessary health care utilization.46 The famous 
report by the Institute of Medicine, Crossing the Quality Chasm, highlighted this issue 
and reported that upon hospital discharge, patients receive little information on self-
management and medication side effects causing unnecessary readmissions. For instance, 
75% of the hospital readmissions among Medicare population are considered potentially 
preventable, resulting in $12 billion in unnecessary Medicare spending each year.46 
 
Several care transitions models have been developed and evaluated. The Care 
Transitions Intervention developed by Eric Coleman utilized nurses and social workers to 
promote development of patient’s skills in four key self-care areas including managing 
medications, timely follow-up care, identifying and responding to ‘red-flags’ (onset of a 
fever or worsening of a condition), and having a patient-centered record owned by the 
patient to simplify information transfer. The program evaluation demonstrated a 30% 
reduction in 30-day hospital readmissions, 17% reduction in 180-day hospital 
readmission, and reduced average cost per patient by 17%. Another care transitions 
model that has been evaluated is the Naylor model developed by Mary Naylor and 
colleagues. The intervention targeted high-risk, high-cost elderly patients and was 
provided for a longer period. The program evaluation reduced readmissions by 36% and 
costs by 39% per patient during 12 months following hospitalization. This program not 
only provided interventions in the hospital setting but also extended it to the community 
setting by incorporating regular home visits. However, care transitions models developed 
so far have not primarily focused on identifying and resolving medication-related issues 
during care transitions. There is a lack of evidence regarding the effectiveness of 
medication management interventions during care transitions, especially among 
vulnerable high-risk patients with chronic conditions and polypharmacy. 
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INTERVENTIONS IMPACTING MEDICATION MANAGEMENT DURING 
CARE TRANSITIONS 
 
Given the increased interest in care transitions and widespread recognition that 
drug therapy problems and medication nonadherence play a major role in readmissions, 
care transitions interventions with a focus on medication management are being 
increasingly explored to reduce drug therapy problems and improve medication 
adherence. Pharmacists can play a central role in care transitions models focused on 
medication management. Pharmacist-led care transitions interventions that have focused 
on comprehensive discharge planning with an emphasis medication reconciliation and 
phone follow-ups have generally been successful in identifying drug therapy problems 
and reducing disease exacerbations and hospitalizations.17,47-52 For instance, in our prior 
study based on SafeMed participants with MCC, polypharmacy, and high health care 
utilization, we found that the Pharmacist-led interventions as part of a care transitions 
program successfully resolved 50% of patients’ medication-related issues, resulting in 
substantial estimated cost savings.13 Schnipper and colleagues found that pharmacist-
provided interventions for patients discharged home from the general medicine service 
was associated with a lower rate of preventable ADE. However, there was no significant 
effect of these interventions on overall ADE or total health care utilization.17 Similarly, 
Ho and colleagues found that among patients with acute coronary syndrome, multifaceted 
pharmacist-led interventions increased adherence to cardioprotective agents one year 
following hospital discharge. However, the intervention did not have any positive effect 
on blood pressure and low-density lipoprotein cholesterol levels.49 A review of studies by 
Kaboli and colleagues examining the effects of pharmacist interventions on processes and 
outcomes in hospitalized adults, demonstrated improvement in quality, safety, and 
efficiency of care.53 In a sample of patients discharged from the hospital to the nursing 
home, Boockvar and colleagues found that pharmacist-conducted medication 
reconciliation and care coordination with physicians reduced medication discrepancies in 
these patients.52 Similarly, Dudas and colleagues found that among patients discharged 
from hospital to home, pharmacist-facilitated discharge process was associated with 
increased patient satisfaction, resolution of medication-related problems and lower ED 
visits.50 And in another study by Phatak and colleagues conducted on patients using high-
risk medications or multiple medications, the pharmacist services provided during care 
transitions reduced readmissions and ED visits.51 
 
There are few studies which did not find any positive effect of care transitions 
based pharmacist-provided medication management interventions. For instance, 
Kripalani and colleagues found that among patients hospitalized with acute coronary 
syndromes or acute decompensated heart failure, the hospital-based pharmacist-led 
interventions did not significantly reduce medication errors after hospital discharge.19 
Additionally, Walker and colleagues found that pharmacist intervention during hospital 
discharge did not significantly reduce readmissions or ED visits in patients who were at 
high risk for medication-related adverse events.54 Although most studies described above 
have shown positive effects of medication management interventions provided during 
care transitions, its effectiveness in vulnerable patient populations with chronic 
conditions and among those experiencing frequent hospitalizations remains unclear. 
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SUPER-UTILIZERS 
 
Super-utilizing patients are those who have high health care costs from recurring, 
preventable inpatient or ED visits. They often face complex medical and social issues55 
and are particularly at risk for drug therapy problems and medication nonadherence 
during care transitions from hospital to the community setting.13,18 A decade ago Dr. 
Jeffrey Brenner, a physician from Camden, NJ, had identified that a small group of 
patients accounted for a bulk of health care costs.55 Since then the interest in super-
utilizers has increased among policymakers, health systems, and researchers. Super-
utilizers represent only 3 to 10% of Medicare and Medicaid population, but are 
responsible for 30 to 50% of the health care spending.56 They often face complex medical 
and social issues including mental health illnesses and substance abuse and frequently 
report chronic pain.56-58 A previous study found that 82% of super-utilizers had MCC and 
41% had a serious mental health diagnosis.56 Another study found that nearly 46% 
patients reported not having a regular primary care provider, and nearly 48% reported 
having severe pain during hospitalization.57 Additionally, Medicaid super-utilizers are 
more likely to have comorbid conditions, behavioral health, and substance abuse 
conditions when compared to Medicare super-utilizers. A study found that among top 
high spending Medicaid super-utilizers, nearly 83% had >3 chronic conditions and about 
60% had >5 conditions.56,59 Because of frequent transitions of care, super-utilizers are at 
high risk for drug therapy problems and medication discrepancies which may cause poor 
adherence. Thus, medication management is critical among high-risk super-utilizing 
patients to achieving optimal therapeutic goals. Despite increased focus on reducing the 
disproportionate health care utilization and costs among super-utilizer, there are very few 
published studies examining these outcomes among the vulnerable super-utilizing patient 
population. And, to our knowledge, no study has focused on the issue of medication 
nonadherence in the super-utilizing population. 
 
 
SAFEMED PROGRAM: A CARE TRANSITIONS PROGRAM WITH A FOCUS 
ON MEDICATION MANAGEMENT 
 
The SafeMed Program was a Centers for Medicare and Medicaid Services (CMS) 
Health Care Innovations Award (HCIA) funded care transitions program with a focus on 
medication management.60 The program included comprehensive targeted interventions 
to improve adherence to safe and effective medications among publicly insured 
(Medicare, Medicaid, or dually eligible), super-utilizers who were admitted to three 
hospitals that were part of a non-profit hospital system in Memphis, TN from February 1, 
2013 to May 1, 2015. The program enrollment occurred during an inpatient admission or 
an observation stay, after which the patients agreeing to participate were provided the 
various intervention services for a minimum of 45 days. A diverse team of health care 
providers, including pharmacists, pharmacy technicians, and nurse practitioners, among 
others, worked in collaboration with physicians to prevent, identify, and resolve any 
drug-related issues, which may lead to low medication adherence and suboptimal 
medication therapy. 
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Pharmacists along with pharmacy technicians worked together to improve the 
care transitions process of patients from the inpatient hospital setting to the community 
setting by providing medication management services. Pharmacist-led interventions as 
part of the SafeMed Program included: comprehensive medication review (CMR), 
targeted medication therapy management (MTM), enhanced discharge planning, home 
visits, phone follow-ups, medication reconciliation during discharge and post-discharge, 
and care coordination with patient’s physicians. The SafeMed model differs from earlier 
care transitions models by focusing explicitly on high risk super-utilizers of inpatient and 
emergency services rather than all hospitalized patients targeted by hospital-focused care 
transitions models such as Project Boost,61 the Bridge Program,62 and Project RED.63 
And unlike other super-utilizer focused care transitions models such as the Camden 
Coalition,64 the Coleman Care Transitions Program,9,65 and the Naylor Transitional Care 
Model,66 SafeMed focused on proven medication therapy management 
approaches19,42 using program pharmacists and pharmacy technicians as key team 
members. 
 
 
CONCEPTUAL FRAMEWORK 
 
The present study uses the Andersen's Behavioral Model of Health Services 
Utilization to demonstrate associations between risk factors, medication nonadherence, 
and inpatient and ED utilization. This model defines the utilization of health services as a 
function of (1) predisposing, (2) enabling, and (3) need factors.67 Predisposing factors 
refer to the individual's characteristics that are present before the illness. These factors 
include the demographic characteristics of age and sex, social factors including 
occupation, education, ethnicity, and social relationships, and health beliefs (attitudes, 
values, knowledge related to health services). Enabling characteristics refer to financing 
and organizational factors. Financial factors include income and wealth that can be used 
to pay for health services or health insurance status. Organizational factors refer to 
whether an individual has a regular source of care and nature of that source. Health 
policies also fall into the category of enabling factors. Need characteristics refer to a 
patient's need to seek health care services. At an individual level, need factors can be 
differentiated as perceived need for health services or evaluated need.  
 
Although, this model was originally developed to predict health services 
utilization, it has been used to predict medication adherence. For instance, Murray and 
colleagues used this model to examine the associations between environmental factors, 
patient characteristics (predisposing, enabling, and need factors), and medication 
adherence to predict utilization outcomes.68 Another study by De Smet and colleagues 
used Andersen’s Behavioral Model to examine self-reported adherence to asthma 
medications and found that better adherence was associated with greater perceived 
asthma severity, longer asthma duration, stronger beliefs in the benefits of treatment, 
among others.69 The conceptual framework for this study is shown in Figure 1-1. In this 
study, we propose that the predisposing, enabling, and need factors predict medication 
nonadherence, and all these factors along with medication nonadherence predict inpatient 
and ED utilization. In this study, the predisposing factors include age, gender, and race.  
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Figure 1-1. Conceptual Framework Based on Anderson Behavioral Model of 
Health Services Utilization 
 
Modified with permission. Andersen RM. Revisiting the behavioral model and access to 
medical care: does it matter? Journal of health and social behavior. Mar 1995;36(1):1-10. 
 
Note: In our study the predisposing factors include age, gender, and race. The enabling 
factors include dual low-income cost sharing subsidy status, ≥1 physician office visits, 
number of unique prescribers, and number of unique pharmacies. The need factors 
include Charlson comorbidity index, mental illness, tobacco use disorder, opioid 
medications filled, and number of unique medications filled. 
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The enabling factors include dual low-income cost sharing subsidy status, >1 physician 
office visits, number of unique prescribers, and number of unique pharmacies. The need 
factors include Charlson comorbidity index, mental illness, tobacco use disorder, opioid 
medications filled, and number of unique medications filled.  
 
 
STUDY SIGNIFICANCE 
 
With the implementation of Hospital Readmissions Reduction Program by the 
Affordable Care Act (ACA), hospitals are being penalized by Medicare for readmissions 
occurring within a month of discharge for conditions including acute myocardial 
infarction and heart failure. This has spurred interest in super-utilizers populations. 
Super-utilizers place a substantial burden on the healthcare system and have become the 
focus of policy initiatives aimed at reducing their disproportionate inpatient and ED 
visits. Hospitals and payers are important stakeholders interested in reducing avoidable 
use of inpatient and ED services among high-risk super-utilizers. Many care transitions 
models are increasingly explored, with varying target populations and focusing on 
different risk factors causing avoidable readmissions and ED use. Medication 
management is a critical component for these high-risk patients since they are at high risk 
for drug therapy problems and medication discrepancies, which may result in poor 
adherence and thereby result in high health care utilization and costs. Given the clinical 
importance of medication nonadherence, it is imperative to understand the magnitude of 
this issue in super-utilizers with chronic conditions.  
 
Numerous studies have examined the risk factors for medication nonadherence in 
different populations and its association with health care utilization, however, to our 
knowledge, such associations have not been established in vulnerable super-utilizers with 
chronic conditions. Additionally, given the increased focus on reducing the 
disproportionate inpatient and ED use in this patient population, it is important to 
understand whether nonadherence to essential chronic medications contributes to their 
high inpatient and ED use. Moreover, considering the high prevalence of mental illness 
and chronic pain in the high-risk super-utilizing population, it is critical to examine 
whether mental illness and opioid medication use are associated with nonadherence and 
health care utilizations in this vulnerable population. Finally, demonstrating the impact of 
an innovative care transitions program on medication adherence will be critical in 
highlighting the central importance of medication management in improving transitions 
of care—that care transitions programs focusing on medication management can improve 
medication use and adherence among vulnerable super-utilizers who can benefit the most 
from such interventions. The study findings may facilitate the adoption of such care 
transitions programs that are targeted towards vulnerable populations and may have the 
potential to impact changes in the future health care delivery, to move in the direction of 
a more patient-centered care transitions program with a focus on medication 
management. 
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RESEARCH AIMS 
 
Using Medicare and Tennessee Medicaid data on super-utilizers with chronic 
conditions, this dissertation aims to investigate the predictors of medication 
nonadherence, association between nonadherence and high inpatient and ED utilization, 
and the impact of the SafeMed Program on medication use and adherence. 
 
 
Aim 1  
 
To examine the prevalence and patterns of medication nonadherence to essential 
chronic medications, and factors associated with medication nonadherence, with special 
emphasis on factors including mental illness and use of opioid medications 
 
x Are demographic, socioeconomic, clinical, therapy complexity, and physician 
office visits associated with overall nonadherence to essential chronic 
medications?  
x Are mental illness and opioid medication use associated with overall 
nonadherence to chronic essential medications? 
 
 
Aim 2 
 
To examine the associations between medication nonadherence, inpatient and 
emergency department use. Additionally, to examine if other risk factors including 
mental illness and opioid medication use, are associated with inpatient and ED use 
 
x Hypothesis 2a: Medication nonadherence to essential chronic medications (overall 
and therapy specific nonadherence) is associated with high inpatient and ED use 
in Medicare beneficiaries <65 years of age 
x Hypothesis 2b: Medication nonadherence to essential chronic medications (overall 
and therapy specific nonadherence) is associated with high inpatient and ED visits 
in Medicare beneficiaries >65 years of age 
x Are mental illness, opioid medication use, and other factors associated with high 
inpatient and emergency department use? 
 
 
Aim 3 
 
To examine the impact of the SafeMed Program on medication use and 
medication adherence 
 
x Hypothesis 3a: SafeMed Program is associated with an increase in medication 
adherence (overall and therapy specific adherence) among the treatment group 
compared to the control group 
x Hypothesis 3b: SafeMed Program is associated with an increase in condition-
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specific medication utilization in the treatment group compared to the control 
group 
x Hypothesis 3c: Does the impact of SafeMed Program on medication adherence 
vary by age, type of public health insurance, and number of comorbidities? 
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CHAPTER 2.    PREDICTORS OF MEDICATION NONADHERENCE IN 
SUPER-UTILIZERS WITH CHRONIC CONDITIONS 
 
 
BACKGROUND 
 
 The disproportionately high health care utilization and resulting colossal 
Medicare spending among a small fraction of Medicare beneficiaries is well 
established.56,70,71 Nearly 50% of the health care spending is incurred by 5% of the 
Medicare population.58 These high-cost health care users are commonly referred to as 
“super-utilizers”.71 They often have complex health and social issues and have high rates 
of multiple chronic conditions (MCC) including mental health disorders.56,58 Substantial 
research shows that patients with MCC and polypharmacy are at high risk of medication 
nonadherence. The therapeutic regimen for patients with MCC is complex, often 
involving multiple concurrent medications, which puts them at greater risk of drug-drug 
interactions and makes these patients less likely to be adherent to their therapy.72-74 In 
addition, patients who experience frequent transitions of care are particularly at higher 
risk of drug therapy problems and medication discrepancies, which may contribute to low 
medication adherence. For instance, after hospital discharge nearly 14% to 75% of 
patients experience medication discrepancies,13,17,18 11% experience adverse drug events 
(ADE),20 and 23% to 48% do not take their medications as directed.14,17 Medication 
management is critical for super-utilizing patients since nonadherence to medications is 
associated with poor health outcomes, and higher hospital admissions and costs.5,38 
 
 The World Health Organization has reported that nearly 50% of patients in 
developed countries do not take their medications as directed by physicians.12 The 
reasons for medication nonadherence are multifactorial, including patient, condition, 
therapy-related, socioeconomic, and health system-related factors.1 Review of existing 
literature demonstrates that the most important factors associated medication 
nonadherence include young age, black race, medication copay, mental illness, multiple 
comorbidities, and therapy complexity, among others.3,7,24-29 However, to our knowledge 
no research has examined the factors associated with medication nonadherence among 
super-utilizers with chronic conditions. Moreover, emerging evidence on super-utilizers 
indicates they have a high prevalence of mental illness and substance use disorder, and 
frequently report chronic pain.56,57,75 For instance, Johnson and colleagues found that 
among publicly insured and uninsured super-utilizers, nearly 41% had a serious mental 
health diagnosis.56 In another study conducted on super-utilizers, Harris and colleagues 
found that nearly 48% of patients reported severe pain (>7 on a 10-point scale).57 
Considering the high prevalence of severe pain in super-utilizing patients, we anticipate 
that the use of opioid medications would be high in this population. Therefore, it is 
imperative to examine whether factors such as mental illness and opioid medication use 
are associated with medication nonadherence in this high-risk population.  
 
Therefore, this study examines, using Medicare administrative claims data, the 
prevalence and patterns of medication nonadherence to essential chronic medications in 
super-utilizers with chronic conditions, and the factors associated with medication 
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nonadherence, with special emphasis on factors including mental illness and use of 
opioid medications.  
 
 
METHODS 
 
 
Design and Setting 
 
 SafeMed Program is a Centers for Medicare and Medicaid Services (CMS) Health 
Care Innovations Award funded care transitions program with a focus on medication 
management.76 The SafeMed Program targeted super-utilizers between February 2013 
and May 2015 who were admitted to three hospitals that were part of a non-profit 
hospital system in Memphis, TN. The present study is a retrospective panel analysis of 
the 2-year baseline data for Medicare Part D beneficiaries meeting the SafeMed Program 
eligibility criteria during the enrollment period from February 2013 to December 2014. 
The study used Medicare beneficiary eligibility, inpatient, outpatient, professional, and 
Part D event files data to document the sociodemographic, clinical, therapy complexity, 
and health services utilization factors associated with medication nonadherence. This 
study included SafeMed eligible patients because they were diagnosed with chronic 
conditions (hypertension, diabetes mellitus, congestive heart failure (CHF), coronary 
artery disease (CAD), chronic obstructive pulmonary disease (COPD), or asthma) that 
have been identified as ambulatory care-sensitive conditions for which outpatient care 
improvements such as improving medication adherence, can reduce inpatient 
utilization.57 Since medication adherence is a dynamic process that changes over time, the 
two-year data for each patient was divided into four 6-month patient-periods. The panel 
design helped us to examine patterns of medication nonadherence in the baseline period 
before the intervention, and the association of time-varying and time-invariant factors 
with medication nonadherence among Medicare super-utilizers. 
 
 
Study Population 
 
 The study included Medicare beneficiaries who were deemed eligible for the 
SafeMed Program during a portion of the enrollment period between February 2013 and 
December 2014. The SafeMed Program eligibility was determined during an inpatient 
admission or an observation stay (index admission). SafeMed Program eligibility was 
based on the following inclusion criteria: 1) adults aged 18 years or older with continuous 
Medicare enrollment, 2) >2 hospital admissions in the past six months OR 1 hospital 
admission and >2 emegerncy department (ED) visits in the six months prior to the index 
admission, and 3) diagnosis of >1 of the following chronic conditions: hypertension, 
CHF, CAD, diabetes mellitus, asthma, or COPD. The International Classification of 
Diseases, Ninth Revision, Clinical Modification [ICD-9-CM codes] for the chronic 
conditions are listed in Appendix A, Table A-1. 
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Patients were excluded from the SafeMed Program if the primary reason for index 
admission was related to cancer, pregnancy, or a surgical procedure for an acute problem 
following the approach of Jencks and colleagues recognizing that health care utilization 
for these conditions is less likely to be affected by outpatient chronic disease care or 
medication management.77 Patients were also excluded if they had diagnoses of active 
psychosis, drug abuse, substance abuse or suicidal ideation during the index admission, 
or if they were discharged to a skilled nursing facility or hospice care because of 
evidence suggesting that these patient populations may be less amenable to outpatient 
intervention.57 The ICD-9-CM codes and diagnosis-related group (DRG) codes for the 
exclusion criteria are listed in a previous paper by Harris and colleagues.57 
 
Of the 1,714 Medicare patients meeting SafeMed inclusion and exclusion criteria 
above, the final sample included the 1,092 (63.7%) who were continuously eligible for 
Medicare Part D during the 2-year evaluation period and who had filled at least one of the 
seventeen drug classes during the 2-year baseline evaluation period. These drug classes 
included angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor 
blockers (ARB), statins, antiplatelet agents, beta-blockers, calcium channel blockers, 
diuretics, alpha-1 blockers, central alpha-2 agonists, direct vasodilators, sulfonylureas, 
biguanides, thiazolidinediones, meglitinides, dipeptidyl peptidase-4 inhibitors, 
anticholinergic inhalers, inhaled corticosteroids alone or in combination with long-acting 
beta-agonists (LABA), and other COPD/asthma medications (theophylline and 
leukotriene modifiers).  
 
 
Study Outcomes 
 
The study’s outcome was repeated measures of medication nonadherence 
measured as interval-based proportion of days covered (PDC).21 PDC was measured 
based on total number of days supplied for each drug class divided by the observation 
time interval for each 6-month period. Drugs that belonged to the same therapeutic class 
(example, amlodipine, and nifedipine in the calcium channel blockers) were considered 
interchangeable. Additionally, based on the evidence-based guideline, ACE inhibitors 
and ARB were considered a single class for this study.78 Antiplatelet agents did not 
include aspirin because aspirin is usually purchased without a prescription (over-the-
counter) and are not included in Part D claims data. Moreover, we did not include insulin 
since the days’ supply information on this drug class is not accurate.79 Interval-based 
PDC was measured if patients had >2 medication fills for any of the seventeen drug 
classes during a 6-month period. Using this approach, the numerator was defined as the 
number of days of medication supplied between the first and last prescription in a period 
and the denominator was defined as the number of days during the interval from the 
index date, which was the first day of the medication fill in a 6-month period, to the last 
day of that period. The average PDC measure was calculated at the patient-level by 
adding the PDC for each drug class and then dividing by the number of drug class used 
by the patient. Patients were then classified as nonadherent if they had PDC<80% over 
the 6-month period. Adherence was also measured based on therapy-specific medication 
adherence classifications, which included diabetes, cardiovascular, and COPD/asthma 
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medications. Additionally, as a sensitivity analysis, we measured adherence by changing 
the fill criteria of >2 medication fills for a drug class to >1 medication fill. 
 
Recognizing that the above definition for measuring PDC might overestimate 
adherence, another sensitivity analysis was conducted using an alternative PDC 
definition—patients were followed continuously from the time they had >2 fills during a 
6-month period for a drug class, to the last 6-month period. We modified the denominator 
by using the first day of medication fill as index date only if patients had >2 fills for a 
drug class for the first time in a period. If patients filled >2 medications for a drug class 
in the previous period, we considered the denominator as 180 days. Additionally, we 
subtracted the inpatient days from the denominator. For the numerator, if the days’ 
supply extended into the next period, it contributed to both periods. 
 
 
Independent Variables 
 
Sociodemographic variables were assessed using Medicare eligibility and 
prescription drug event files. Age, gender, and race/ethnicity were measured at baseline. 
Other sociodemographic factors measured for each 6-month period included whether 
patients were fully or partially eligible as dual beneficiaries in >1 months and whether 
patients received low-income cost sharing subsidy (LICS) for the index drug classes. The 
income threshold to be eligible for Tennessee Medicaid (TennCare) is 105% of the 
federal poverty level (FPL), while the income threshold for receiving LICS is higher—
150% of the FPL. We combined these factors to create a variable with three groups (non-
dual non-LICS, non-dual LICS, and dual LICS). 
 
Clinical factors that were assessed at baseline included information on whether 
beneficiaries qualified for Medicare because of end-stage renal disease (ESRD) and 
whether beneficiaries had any disability. Disability was not included in the bivariate and 
multivariate models since everyone <65 years of age was also disabled. The ICD-9 
diagnosis codes present on at least one Medicare inpatient, outpatient, or Part B claim 
were used to identify patients in each 6-month period who had qualifying chronic 
conditions or comorbidities. Overall comorbidity was measured using the University of 
Manitoba SAS Macro for Charlson comorbidity index (mean).80 Additionally, the 
SafeMed Program’s qualifying chronic conditions included: diabetes, hypertension, CHF, 
CAD, COPD, and asthma. We only included Charlson comorbidity index in the bivariate 
and multivariate models as a comorbidity measure, since it includes the qualifying 
conditions and ESRD. In addition to this, we assessed mental illness (defined as a 
diagnosis of depression or anxiety or >1 anxiolytic or antidepressant fills) and tobacco 
use disorder. The ICD-9-CM codes for anxiety, depression, and tobacco use disorder are 
listed in Appendix A, Table A-1. 
 
Therapeutic complexity and health services utilization factors were assessed for 
each 6-month period, using prescription drug event and Part B claims files. Therapeutic 
complexity-related factors included the number of unique medications filled, opioid 
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medications filled (0, 1, 2-3, or >4 fills), number of unique prescribers, and number of 
unique pharmacies. Health services utilization factors included >1 physician office visits. 
 
 
Statistical Analysis 
 
Descriptive analyses were conducted to show the characteristics of super-utilizers 
and medication nonadherence rates in each 6-month period. For bivariate and 
multivariate analyses, we pooled observations from the four 6-month periods. The unit of 
analysis for the bivariate and multivariate models was patient-period. Chi-square tests 
and t-tests were conducted as part of the bivariate statistics. We used random effects 
model with a binary distribution to obtain associations between independent variables 
and medication nonadherence. The model included lagged effects of comorbidities, 
therapy complexity, and physician office visits. As a subgroup analysis, we estimated 
separate multivariate models for each age group (i.e., <65 and >65 years) to understand 
associations specific to these Medicare age groups. Data cleaning was performed using 
SAS 9.4 and all data analyses were conducted using STATA 13. Variables in the 
multivariate models with P<0.05 were considered significant. 
 
 
RESULTS 
 
Characteristics of the study population (N=1,092) in each 6-month evaluation 
period is shown in Table 2-1. The mean age of the study population was 65.1 years, and, 
43.0% were <65 years of age. The study population was predominantly female (58.8%), 
non-Hispanic Black (68.6), dual eligible (63.7%), and received LICS (68.7%). In the 
fourth period, patients had a mean of 3.1 inpatient stays and 1.7 ED visits. Additionally, 
in the same period, 97.2% of the study patients had >2 chronic conditions, 57.0% were 
diagnosed with depression/anxiety or had filled >1 antidepressants or anxiolytics, and 
69.0% had filled >1 opioid medications. These proportions were higher in the fourth 
period than previous periods. 
 
Rates of nonadherence to essential chronic disease medications are shown in 
Table 2-2. We found that 40.4% of patients were nonadherent to their diabetes 
medications, 48.2% to their cardiovascular medications, and 54.3% to their 
COPD/asthma medications. Nonadherence rates for cardiovascular and COPD/asthma 
medications were higher in the fourth period than previous periods. When examining 
overall nonadherence rate, we found that 45.7% of patients were nonadherent to their 
essential chronic medications. 
 
 
Main Analysis 
 
Bivariate associations with medication nonadherence are shown in Table 2-3. In 
the multivariate analysis (Table 2-4), we found that patients who filled >4 opioid 
medications in the previous period had higher odds of medication nonadherence 
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Table 2-1. Characteristics of the Study Sample in Each 6-Month Patient-Period (N=1,092) 
 
Characteristics Period 1 Period 2 Period 3 Period 4 
 N (%) N (%) N (%) N (%) 
Age 
<65 years 
>65 years 
mean age (SD) 
 
468 (42.9) 
624 (57.1) 
65.1 (14.5) 
 
- 
 
 
 
- 
 
- 
 
Female 642 (58.8) - - - 
Race/Ethnicity 
Non-Hispanic White 
Non-Hispanic Black 
Other 
 
326 (29.9) 
749 (68.6) 
17 (1.6) 
 
- 
 
- 
 
 
- 
 
 
Eligibility status 
Disabled 
End-stage renal disease 
Dual eligible 
Receiving low-income cost sharing subsidy 
 
407 (37.3) 
324 (29.7) 
696 (63.7) 
750 (68.7) 
 
- 
- 
694 (63.6) 
790 (72.3) 
 
- 
- 
697 (63.8) 
791 (72.4) 
 
- 
- 
692 (63.4) 
803 (73.5) 
Qualifying Chronic Conditions 
Diagnosis of Hypertension 
Diagnosis of Diabetes 
Diagnosis of Congestive heart failure 
Diagnosis of Coronary artery disease 
Diagnosis of Asthma 
Diagnosis of Chronic obstructive pulmonary 
disease 
Number of qualifying chronic conditions 
<1 chronic conditions 
2 chronic conditions 
3 chronic conditions 
4 or more chronic conditions 
 
852 (78.0) 
571 (52.3) 
338 (31.0) 
368 (33.7) 
134 (12.3) 
246 (22.7) 
 
 
335 (30.82) 
262 (24.0) 
247 (22.6) 
246 (22.5) 
 
950 (87.0) 
638 (58.4) 
467 (42.8) 
481 (44.1) 
199 (18.2) 
343 (31.4) 
 
 
226 (20.7) 
236 (21.6) 
244 (22.3) 
386 (35.3) 
 
1,028 (94.1) 
696 (63.7) 
603 (55.2) 
590 (54.0) 
262 (24.0) 
448 (41.0) 
 
 
131 (12.0) 
204 (18.7) 
250 (23.0) 
507 (46.4) 
 
1086 (99.5) 
784 (71.8) 
799 (73.2) 
785 (71.9) 
377 (34.5) 
583 (53.4) 
 
 
31 (2.8) 
115 (10.5) 
211 (19.3) 
735 (67.2) 
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Table 2-1. Continued 
 
Characteristics Period 1 Period 2 Period 3 Period 4 
 N (%) N (%) N (%) N (%) 
Comorbidity 
Charlson comorbidity index, mean (SD) 
Mental illness* 
Tobacco use disorder 
 
3.2 (2.7) 
389 (35.6) 
106 (9.7) 
 
4.2 (3.1) 
460 (42.1) 
163 (14.9) 
 
5.2 (3.3) 
533 (48.8) 
266 (24.4) 
 
6.9 (3.2) 
622 (57.0) 
351 (32.1) 
Therapy complexity 
No. of unique medications filled, mean 
(SD) 
No. of unique prescribers 
No. of unique pharmacies 
No. of opioids filled, mean (SD) 
0 opioid filled   
1 opioid filled 
2-3 opioid filled 
>4 opioid filled 
 
11.9 (6.2) 
4.4 (2.9) 
1.8 (1.3) 
2.6 (4.0) 
499 (45.7) 
147 (13.5) 
159 (14.6) 
287 (26.3) 
 
12.3 (6.4) 
4.6 (3.0) 
1.8 (1.3) 
2.7 (4.0) 
479 (43.9) 
165 (15.1) 
143 (13.1) 
305 (27.9) 
 
12.5 (6.5) 
4.7 (3.0) 
1.9 (1.3) 
2.7 (3.9) 
480 (44.0) 
157 (14.4) 
151 (13.8) 
304 (27.8) 
 
14.9 (6.3) 
5.8 (3.1) 
2.1 (1.4) 
3.2 (4.1) 
337 (31.0) 
187 (17.1) 
211 (19.3) 
357 (32.7) 
Health services utilization 
>1 physician office visits± 
No. of inpatient stays, mean (SD) 
No. of emergency department visits, mean 
(SD) 
 
900 (82.4) 
0.8 (1.4) 
0.8 (2.1) 
 
903 (82.7) 
0.8 (1.4) 
0.8 (2.2) 
 
909 (83.2) 
0.7 (1.4) 
0.9 (2.2) 
 
915 (83.8) 
3.1 (0.9) 
1.7 (2.6) 
 
±Physician office visits were identified using Part B claims and were defined as “location, other than a hospital, skilled nursing facility 
(SNF), military treatment facility, community health center, State or local public health clinic, or intermediate care facility (ICF), 
where the health professional routinely provides health examinations, diagnosis, and treatment of illness or injury on an ambulatory 
basis.”  
*Mental illness was defined as >1 antidepressants or anxiolytics fill or diagnosis of depression/anxiety. 
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Table 2-2. Medication Nonadherence to Essential Chronic Disease Medications 
by Therapy Class 
 
Therapy Class Percent Nonadherent  
 (PDC<80%) 
1. Diabetes medications 
Period 1 (n=250) 
Period 2 (n=240) 
Period 3 (n=232) 
Period 4 (n=194) 
Overall (n=916 patient-periods) 
 
41.2% 
40.8% 
38.8% 
40.7% 
40.4% 
2. Cardiovascular medications 
Period 1 (n=933) 
Period 2 (n=942) 
Period 3 (n=932) 
Period 4 (n=976) 
Overall (n=3,763 patient-periods) 
 
40.2% 
44.5% 
41.0% 
47.4% 
48.2% 
3. COPD/Asthma medications* 
Period 1 (n=169) 
Period 2 (n=166) 
Period 3 (n=169) 
Period 4 (n=183) 
Overall (n=687 patient-periods) 
 
54.4% 
53.6% 
49.7% 
59.6% 
54.3% 
Diabetes, cardiovascular, and COPD/Asthma 
meds combined 
Period 1 (n=961) 
Period 2 (n=971) 
Period 3 (n=961) 
Period 4 (n=994) 
Overall (n=3,892 patient-periods) 
 
 
43.2% 
45.9% 
42.6% 
50.9% 
45.7% 
 
COPD: chronic obstructive pulmonary disease. 
*COPD/Asthma medications included controller medications (anticholinergic inhalers, 
inhaled corticosteroids alone or in combination with long-acting beta-agonists (LABA), 
and other COPD/asthma medications (theophylline and leukotriene modifiers). 
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Table 2-3. Bivariate Associations with Medication Nonadherence (N=2,828 
Patient-Periods) 
 
Characteristics Adherence  Nonadherence  P Value 
 N (%) N (%)  
Age  
<65 years 
>65 years 
 
512 (33.5) 
1,018 (66.5) 
 
640 (49.3) 
658 (50.7) 
 
 
<0.001 
Female  932 (60.9) 780 (60.1) 0.656 
Race 
Non-Hispanic White/other 
Non-Hispanic Black 
 
538 (35.2) 
992 (64.8) 
 
365 (28.1) 
933 (71.9) 
 
 
<0.001 
Eligibility status 
Non-dual and non-LIS 
Non-dual LIS 
Dual LIS 
 
472 (30.9) 
151 (9.9) 
907 (59.3) 
 
279 (21.5) 
132 (10.2) 
887 (68.3) 
 
 
 
<0.001 
Comorbidity 
Charlson comorbidity index, mean (SD) 
Diagnosis of tobacco abuse disorder  
Mental illness* 
 
4.3 (3.1) 
282 (18.4) 
635 (41.5) 
 
4.6 (3.2) 
258 (19.9) 
521 (40.1) 
 
0.030 
0.330 
0.462 
Therapy complexity 
No. of unique medications filled, mean 
(SD) 
Opioid Medication Use 
0 opioid medication filled  
1 opioid medication filled 
2-3 opioid medications filled 
>4 opioids medications filled 
No. of unique prescribers 
No. of unique pharmacies 
 
12.9 (5.9) 
 
 
720 (47.1) 
215 (14.1) 
227 (14.8) 
368 (24.1) 
4.5 (2.8) 
1.8 (1.1) 
 
13.3 (6.3) 
 
 
503 (38.8) 
195 (15.0) 
167 (12.9) 
433 (33.4) 
5.1 (3.2) 
2.0 (1.4) 
 
0.174 
 
 
<0.001 
 
 
 
<0.001 
<0.001 
Health care utilization 
>1 physician office visits  
 
 
1,333 (87.1) 
 
1,070 (82.4) 
 
0.001 
 
Significant at P<0.05. The bivariate tests included lagged effects of comorbidity, therapy 
complexity-related, and health care utilization factors. 
*Mental illness was defined as >1 antidepressants or anxiolytics fill or diagnosis of 
depression/anxiety. 
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Table 2-4. Multivariate Association with Medication Nonadherence (N=2,828 
Patient-Periods) 
 
Characteristics Nonadherence P Value 
 Odds Ratio (95% CI)  
<65 years 2.15 (1.54-2.99) <0.001 
Female 1.01 (0.75-1.38) 0.931 
Non-Hispanic black 1.17 (0.84-1.63) 0.343 
Non-dual Non-LICS (Ref) 
Non-dual LICS 
Dual LICS 
 
1.10 (0.66-1.83) 
1.47 (1.02-2.13) 
 
0.708 
0.039 
Comorbidity 
Charlson comorbidity index 
Mental illness* 
Diagnosis of tobacco abuse disorder  
 
1.02 (0.98-1.07) 
0.79 (0.58-1.08) 
0.82 (0.58-1.16) 
 
0.330 
0.140 
0.264 
Medication related factors 
No. of unique medications filled 
Opioid Medication Use 
0 opioid medication filled (Ref) 
1 opioid medication filled 
2-3 opioid medications filled 
>4 opioid medications filled 
No. of unique prescribers 
No. of unique pharmacies 
 
0.96 (0.93-0.98) 
 
 
1.30 (0.93-1.82) 
1.02 (0.71-1.46) 
1.94 (1.34-2.82) 
1.09 (1.03-1.15) 
1.02 (0.92-1.14) 
 
0.006 
 
 
0.128 
0.914 
<0.001 
0.003 
0.671 
Health care utilization 
>1 physician office visits  
 
0.57 (0.40-0.81) 
 
0.002 
 
Significant at P<0.05. The model included lagged effects of comorbidity, therapy 
complexity-related, and health care utilization factors. 
*Mental illness was defined as >1 antidepressants or anxiolytics fill or diagnosis of 
depression/anxiety. 
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compared to patients with no opioid fill (odds ratio (OR), 1.94; 95% confidence interval 
(CI), 1.34-2.82; P<0.001). Compared to patients with no mental illness, those with 
mental illness had lower odds of nonadherence, however this association was not 
statistically significant (OR, 0.79; CI, 0.58-1.08; P=0.140). Among sociodemographic 
factors, patients 22-64 years of age were more likely to be nonadherent than patients >65 
years (OR: 2.15; CI: 1.54-2.99; P<0.001), and dual beneficiaries who received LICS 
were more likely to be nonadherent than non-dual beneficiaries with no LICS CI, 1.02-
2.13; P=0.039). Among therapy complexity-related factors, patients who had higher 
number of unique prescribers were more likely to be nonadherent (OR, 1.09; CI, 1.03-
1.15; P=0.003), whereas patients who filled higher number of different medications were 
less likely to be nonadherent (OR, 0.96; CI, 0.93-0.98; P=0.006). Finally, we found that 
patients who had >1 physician office visits in the previous period were less likely to be 
nonadherent to their essential chronic medications (OR, 0.57; CI, 0.40-0.81; P=0.002).   
 
Table 2-5 shows the multivariate associations among Medicare beneficiaries >65 
years of age. Risk factors for nonadherence in this age group included >4 opioid 
medications filled in the previous period and higher number of unique prescribers. 
Additionally, we found that >1 physician office visits in the previous period was 
protective against nonadherence. Table 2-6 shows the multivariate associations among 
Medicare beneficiaries <65 years of age. Risk factors for nonadherence included >4 
opioid medications filled in the previous period and dual LICS status. Higher number of 
unique medications filled was found to be protective against nonadherence.  
 
 
Sensitivity Analysis 
 
Our main adherence definition—based on patients who had at least >2 fills in a 
period—may underestimate nonadherence because it did not include patients who had 
only one fill or did not fill their medications in subsequent periods. Using the alternative 
PDC definition that assumes continuous chronic disease drug class use once begun (>2 
fills for a drug class in a period), proportion of patients who were nonadherent was about 
13% higher (58.4%) (Appendix A, Table A-2). The multivariate model using this 
alternate PDC calculation demonstrated similar findings in terms of direction and 
statistical significance to our main analysis in terms of age, dual LICS status, number of 
different medications filled, unique prescribers, and physician office visits. However, 
there were a few differences: comorbidity index was found to be significantly associated 
with nonadherence and the association between opioid medication fill and nonadherence 
was no longer statistically significant (Appendix A, Table A-3). Additionally, in the 
sensitivity analysis using the alternative PDC criteria of >1 medication fill for our main 
PDC definition (Appendix A, Table A-4), the study findings were similar in terms of 
significance and directionality to our main multivariate analysis.  
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Table 2-5. Multivariate Association with Medication Nonadherence Among 
Medicare Beneficiaries ≥65 Years of Age (N=1,676 Patient-Periods) 
 
Characteristics Nonadherence P Value 
 Odds Ratio (95% CI)  
Female 1.15 (0.77-1.71) 0.494 
Non-Hispanic black 1.09 (0.71-1.68) 0.684 
Non-dual Non-LICS (Ref) 
Non-dual LICS 
Dual LICS 
 
0.90 (0.48-1.72) 
1.29 (0.84-1.97) 
 
0.759 
0.242 
Comorbidity 
Charlson comorbidity index 
Mental illness* 
Diagnosis of tobacco abuse disorder  
 
1.03 (0.97-1.10) 
0.73 (0.48-1.11) 
0.78 (0.45-1.35) 
 
0.330 
0.143 
0.373 
Medication related factors 
No. of unique medications filled 
Opioid Medication Use 
0 opioid medication filled (Ref) 
1 opioid medication filled 
2-3 opioid medications filled 
>4 opioid medications filled 
No. of unique prescribers 
No. of unique pharmacies 
 
0.96 (0.91-1.02) 
 
 
1.30 (0.85-2.00) 
1.04 (0.66-1.63) 
1.89 (1.14-3.12) 
1.14 (1.04-1.24) 
0.95 (0.80-1.13) 
 
0.155 
 
 
0.228 
0.876 
0.013 
0.004 
0.588 
Health care utilization 
>1 physician office visits  
 
0.50 (0.31-0.80) 
 
0.004 
 
Significant at P<0.05. The model included lagged effects of comorbidity, therapy 
complexity-related, and health care utilization factors. 
*Mental illness was defined as ≥1 antidepressants or anxiolytics fill or diagnosis of 
depression/anxiety. 
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Table 2-6. Multivariate Association with Medication Nonadherence Among 
Medicare Beneficiaries <65 Years of Age (N=1,152 Patient-Periods) 
 
Characteristics Nonadherence P Value 
 Odds Ratio (95% CI)  
Female 0.90 (0.57-1.43) 0.648 
Non-Hispanic black 1.34 (0.78-2.30) 0.296 
Non-dual Non-LICS (Ref) 
Non-dual LICS 
Dual LICS 
 
0.99 (0.80-4.92) 
2.58 (1.18-5.61) 
 
0.139 
0.017 
Comorbidity 
Charlson comorbidity index 
Mental illness* 
Diagnosis of tobacco abuse disorder  
 
0.71 (0.41-1.23) 
0.86 (0.54-1.36) 
0.83 (0.54-1.28) 
 
0.221 
0.522 
0.397 
Medication related factors 
No. of unique medications filled 
Opioid Medication Use 
0 opioid medication filled (Ref) 
1 opioid medication filled 
2-3 opioid medications filled 
>4 opioid medications filled 
No. of unique prescribers 
No. of unique pharmacies 
 
0.95 (0.90-0.99) 
 
 
1.16 (0.68-1.96) 
0.85 (0.49-1.47) 
1.83 (1.08-3.11) 
1.03 (0.96-1.10) 
1.09 (0.95-1.26) 
 
0.035 
 
 
0.583 
0.570 
0.025 
0.370 
0.205 
Health care utilization 
>1 physician office visits  
 
0.71 (0.41-1.23) 
 
0.221 
 
Significant at P<0.05. The model included lagged effects of comorbidity, therapy 
complexity-related, and health care utilization factors. 
*Mental illness was defined as ≥1 antidepressants or anxiolytics fill or diagnosis of 
depression/anxiety. 
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DISCUSSION 
 
This study is the first to focus specifically on the prevalence and factors 
associated with medication nonadherence in super-utilizers with chronic conditions. We 
found high rates of medication nonadherence among super-utilizers with chronic 
conditions. Specifically, we found that the overall nonadherence rate for essential chronic 
disease medications ranged from 45.7% to 58.4%, with the highest rate for 
COPD/Asthma medications (54.3% to 64.4%). The high rates of nonadherence found in 
this study are similar to those previously found in patients using diabetes, cardiovascular, 
and COPD/asthma medications.3,15,81-83 However, this study extends these findings to 
super-utilizing Medicare population and provides important information to the super-
utilizer literature. We not only found high rates of nonadherence among super-utilizers 
but also saw an increase in the nonadherence rates in the final 6-month period when 
patients had more frequent hospitalizations and ED visits. The study findings suggest that 
medication nonadherence is a significant problem among super-utilizers with chronic 
conditions, and greater efforts may be needed to address this issue. 
 
Our study shows that most super-utilizers have high rates of mental illness and 
opioid use. During the final 6-month evaluation period, 57% were diagnosed with 
depression or anxiety or had filled antidepressants or anxiolytics, and 69% had filled 
opioid medications. A substantial amount of opioid utilization is likely driven by the high 
prevalence of chronic pain in the SafeMed population as documented in a previous 
study.57 To our knowledge this is the first study to document the association between 
opioid medication fill and medication nonadherence among super-utilizers and provides 
evidence of high opioids use as a risk factor for medication nonadherence. These findings 
highlight the barrier to achieving optimal adherence in super-utilizers due to high opioid 
use and the need for effective strategies to address medication nonadherence among 
opioid-consuming super-utilizers. Our results for depression/anxiety were not consistent 
with the previous studies which found these conditions to be associated with 
nonadherence.24,84-87 We did not find any significant association of anxiety/depression or 
filling anxiolytic/antidepressants with nonadherence to essential chronic medications in 
the main analysis. 
 
This study provides insight into the characteristics of super-utilizers who are at 
higher risk of medication nonadherence. In this study, non-elderly Medicare beneficiaries 
represented 43% of the study population, approximately 92% of whom received LICS, 
and 80% were both dual-eligible and LICS recipients. Unlike other studies based on 
Medicare data that have shown better or similar medication adherence for duals and those 
receiving LICS compared to non-dual non-LICS beneficiaries,88,89 we found lower 
adherence for duals receiving LICS. This is probably because our study population, 
unlike those of previous studies, had high representation of younger dual eligible 
beneficiaries, who had on average higher comorbidity index values and opioid 
medication use than patients >65 years of age. Moreover, previous studies conducted on 
different populations have shown that young age is associated with lower medication 
adherence.1,3 Our study findings show that medication cost subsidies are not enough to 
achieve optimal adherence in these high-risk patients, especially for non-elderly 
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Medicare beneficiaries. The highly statistically significant and large effect size of the 
association between age and medication nonadherence demonstrates the need for better 
targeting of the non-elderly Medicare group with medication management interventions. 
Our sub-group analysis shows that the factors associated with nonadherence vary across 
age groups. Examining associations separately in the two age groups may help 
researchers to better target these high utilizing patient populations with medication 
management interventions. 
 
The study found that higher physician office visits were associated with 
significant higher medication adherence, consistent with the findings of other studies.3,5 
The statistically strong association between physician office visits and lower 
nonadherence suggests the importance of making routine visits to providers who can play 
a significant role in helping patients to adhere to their essential chronic medications. This 
finding may also be an indicator for more health consious patients who are more likely to 
visit their providers. 
 
Of note, increased number of different medications filled was associated with 
lower odds of nonadherence. Other studies evaluating this relationship have reported 
mixed results. For instance, Bailey and colleagues found that among Tennessee’s 
Medicaid patients with hypertension, the number of hypertensive drug classes filled was 
associated with lower odds of nonadherence.3 Similarly, Choudhry and colleagues found 
that in patients who were prescribed a cardiovascular medication, those with a large 
number of concurrent medications were more likely to be adherent.73 However, Chapman 
and colleagues found that patients consuming a higher number of other medications had 
lower adherence to lipid lowering and antihypertensive medications.90 Filling a higher 
number of concurrent medications may represent behavioral characteristics of patients 
who are more likely to use a higher number of medications and also adhere to their 
therapy. When examining other therapy complexity-related factors, we found that a 
higher number of unique prescribers was associated with higher odds of nonadherence. 
This finding was consistent with the finding of Choudhry and colleagues who also found 
higher number of prescribers being associated with poor adherence.73  
 
This study has important implications. The literature on super-utilizers is sparse 
and mainly focuses on describing the population and their hospitalization patterns.56,57 To 
our knowledge, this study is the first to focus on the issue of medication nonadherence in 
super-utilizers with chronic conditions. The risk factors identified in this study may 
enable accountable care organizations and managed care organizations identify super-
utilizing populations in need of medication management interventions. Managing 
medication-related adverse events and improving medication adherence among 
vulnerable super-utilizers is critical for hospitals and payers, since 75% of the hospital 
readmissions among Medicare population are considered potentially preventable, 
resulting in $12 billion in unnecessary Medicare spending each year and subjecting 
hospitals to readmission penalties.46 Our findings suggest that super-utilizers using >4 
opioid medications are at particular risk for nonadherence and may merit targeted 
medication management interventions to support essential chronic disease medication 
adherence. Given the magnitude and clinical importance of medication nonadherence in 
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this population, a more collaborative and holistic approach may be needed to improve 
adherence in this high-risk population, who experience frequent care transitions exposing 
them to higher drug therapy problems and medication discrepancies. Medication 
management interventions conducted on other populations have demonstrated mixed 
results,17,19,44,45 and care transitions programs targeting super-utilizers have not primarily 
focused on medication management.65,91 For instance, Pringle and colleagues evaluated 
the impact of a large-scale, pharmacy-based intervention on five chronic medication 
classes among Medicare, Medicaid, or commercial patients and found that, compared to 
the control group, the intervention group had improved adherence for all medication 
classes.43 However, Kripalani and colleagues, who examined the effect of pharmacist 
interventions on clinically important medical errors after hospital discharge among 
Medicare, Medicaid, or private pay patients, did not find any positive effect of these 
interventions on medication errors.19 Our results suggest the potential for novel care 
transitions programs aimed at improving medication adherence. 
 
Our study is also subject to several limitations. First, the study used administrative 
data and had to rely on the variables that were available in the database. Medicare claims 
data does not capture some of the important variables such as health literacy, social 
support, satisfaction with health care, and other healthcare system factors that may impact 
medication adherence in vulnerable super-utilizers. Second, although pharmacy fill data 
is widely used to assess medication adherence, we cannot be certain that patients who fill 
medications are also using them appropriately. To address limitations of using claims 
based PDC, we calculated PDC using two different definitions, which allowed for 
checking the reliability of our main findings. Using these approaches, the overall 
nonadherence rate ranged from 45.7% to 58.4% and most of the findings of multivariate 
models remained similar. Given that the main approach could overestimate adherence 
and the alternative methods could underestimate adherence, we suspect that the 
population estimates for nonadherence of these super-utilizers could lie somewhere 
between the nonadherence ranges reported in this study. Third, the PDC measure for 
calculating adherence is an indirect method and may not accurately capture medication 
use and is likely to be biased for inhalation products that are prescribed for Asthma and 
COPD. Finally, since this study is based on super-utilizers living in Memphis, TN, the 
study findings may only be generalizable to similar populations and similar settings 
across the country. 
 
 
CONCLUSION 
 
In summary, the overall medication nonadherence rate for essential chronic 
disease medications was high among super-utilizers, especially in patients using 
COPD/Asthma medications. Previously identified factors—including physician office 
visits, a higher number of medications—were found to protect against nonadherence, 
while young age, dual LICS status, and higher number of unique prescribers predicted 
nonadherence. Of note, opioid medication use was identified as a novel and significant 
risk factor for essential medication nonadherence in super-utilizers with chronic 
conditions.  
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CHAPTER 3.    ASSOCIATION BETWEEN MEDICATION NONADHERENCE 
AND INPATIENT AND EMERGENCY DEPARTMENT USE IN SUPER-
UTILIZERS WITH CHRONIC CONDITIONS 
 
 
BACKGROUND 
 
Consistent and long-term use of prescription medications is critical for the 
treatment of chronic conditions, such as heart disease, diabetes, hypertension, and chronic 
lung disease. Nonadherence to needed drugs could be a major barrier to achieving 
optimal treatment goals, especially among high-risk patient populations. Super-utilizers 
represent one such vulnerable patient population — patients with disproportionately high 
inpatient and emergency department (ED) use, who have multiple chronic conditions 
(MCC) and use multiple concurrent medications to treat these conditions.13,55,56 The cost 
of caring for super-utilizers is high, with estimates showing that they represent only 3 to 
5% of the U.S. population, but account for 30 to 50% or more of total spending.56,70 
Additionally, these super-utilizing patients experience frequent transitions of care and are 
particularly vulnerable to experiencing drug therapy problems, medication discrepancies, 
and medication nonadherence at each care transition.13,19  
 
Previous studies using longitudinal data have shown improved medication 
adherence to be associated with lower inpatient and ED use. Roebuck and colleagues 
found that improved medication adherence was associated with lower hospitalization and 
ED use in patients with congestive heart failure, hypertension, diabetes, or dyslipidemia.5 
Another study by Jha and colleagues also found lower hospitalization or ED rates 
associated with improved adherence to diabetes medications.4 Despite widespread 
recognition that medication nonadherence plays a significant role in hospitalizations, 
such associations have not been established for super-utilizers with chronic conditions. 
Given the increased focus on reducing the disproportionate health care utilization and 
costs in this patient population, it is important to understand whether nonadherence to 
essential chronic medications contributes to their high inpatient and ED use. 
 
High rates of mental illness and chronic pain have been reported among super-
utilizing patient populations.56-58 Additionally, evidence from our previous study on 
Medicare super-utilizers demonstrates that along with the high prevalence of medication 
nonadherence and mental illness, these patients have higher rates of opioid medication 
use (Chapter 2). However, little is known whether these factors are associated with high 
inpatient and ED use. A recent study found that opioid use is common after 
hospitalization among Medicare beneficiaries.92 However, it is not clear whether recent 
opioid use has any association with high health care utilization. Using longitudinal 
Medicare administrative data, we examined the association between medication 
nonadherence and inpatients and ED use in a cohort of Medicare super-utilizers with 
chronic conditions. Additionally, we also evaluated if other risk factors, including mental 
illness and opioid medication use, are associated with inpatient and ED utilization in this 
vulnerable high-risk population.  
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METHODS 
 
 
Design and Setting 
 
SafeMed Program is a Centers for Medicare and Medicaid Services (CMS) Health 
Care Innovations Award funded care transitions program with a focus on medication 
management.60 The program targeted super-utilizers from medically underserved areas 
admitted to a non-profit hospital system in Memphis, TN from February 2013 to May 
2015. Using Medicare administrative data, we conducted a retrospective panel data 
analysis of the 2-year baseline data for Medicare Part D beneficiaries meeting the 
SafeMed Program eligibility criteria during the enrollment period from February 1, 2013 
to December 31, 2014. The study included SafeMed eligible patients because they were 
diagnosed with chronic conditions (hypertension, diabetes mellitus, congestive heart 
failure (CHF), coronary artery disease (CAD), diabetes mellitus, asthma, or chronic 
obstructive pulmonary disease (COPD)) that have been identified as ambulatory care-
sensitive conditions for which outpatient care improvements can reduce inpatient 
utilization.57 The two-year baseline data for each patient was divided into four 6-month 
patient-periods, the last 6-month period being the qualifying period for the SafeMed 
Program. Previous studies on super-utilizers have shown that super-utilizer status is not 
consistent, and it changes over time.56,57 The panel design enabled us to examine the 
changes in medication adherence and health care utilization over the 2-year period prior 
to the intervention and to understand whether the time-varying factor, medication 
nonadherence, was associated with inpatient and ED utilization.  
 
 
Study Population 
 
This study included Medicare beneficiaries who were eligible for the SafeMed 
Program during a portion of the enrollment period between February 2013 and December 
2014. Patients were enrolled in the SafeMed Program during an inpatient admission or an 
observation stay (index hospitalization). SafeMed Program eligibility was based on the 
following inclusion criteria: 1) adults aged 18 years or older with continuous Medicare 
enrollment, 2) >2 hospital admissions in the past six months OR 1 inpatient admission 
and >2 ED visits in the past six months prior to the index admission, and 3) diagnosis of 
>1 of the following chronic conditions: hypertension, CHF, CAD, diabetes mellitus, 
asthma, or COPD.  
 
Additionally, patients were excluded from the SafeMed Program if the primary 
reason for index admission was related to cancer, pregnancy, or a surgical procedure for 
an acute problem following the approach of Jencks and colleagues recognizing that 
utilization for these conditions is less likely to be affected by outpatient chronic disease 
care or medication management.77 Patients were also excluded if they had diagnoses of 
active psychosis, drug abuse, substance abuse or suicidal ideation during the index 
admission, or if they were discharged to a skilled nursing facility or hospice care because 
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of evidence suggesting that high utilization in these patient populations may be less 
amenable to outpatient intervention.57  
 
Of the 1,714 Medicare patients meeting SafeMed inclusion and exclusion criteria 
above, the final sample included the 1,092 (63.7%) who were continuously eligible for 
Medicare Part D during the 2-year evaluation period and who had filled at least one of the 
seventeen drug classes during the 2-year baseline evaluation period: These drug classes 
included angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor 
blockers (ARB), statins, antiplatelet agents, beta-blockers, calcium channel blockers, 
diuretics, alpha-1 blockers, central alpha-2 agonists, direct vasodilators, sulfonylureas, 
biguanides, thiazolidinediones, meglitinides, dipeptidyl peptidase-4 inhibitors, 
anticholinergic inhalers, inhaled corticosteroids alone or in combination with long-acting 
beta-agonists (LABA), and other COPD/asthma medications (theophylline and 
leukotriene modifiers).  
 
 
Outcome Variables 
 
This study included two outcomes: 1) total number of inpatient and observation 
stays and 2) total number of ED visits, measured for each 6-month period. Data on 
inpatient stays was obtained using MEDPAR (Medical Provider Analysis and Review) 
data files. Additionally, data on observation stays and ED visits were obtained using 
Medicare outpatient revenue center data files (revenue center codes for ED visits: 0450-
0459, 0981; revenue center codes for observation stays: 0762). We excluded observation 
stays and ED visits that resulted in an inpatient admission. 
 
 
Independent Variables 
 
Medication nonadherence 
 
The Medicare Part D drug event data was used to assess medication 
nonadherence. Medication nonadherence was measured as interval-based proportion of 
days covered (PDC).21 PDC was measured based on total number of days’ supply for 
each drug class divided by the observation time interval for each 6-month period. We 
measured PDC for the drug classes mentioned above. Drugs that belonged to the same 
therapeutic class (example, amlodipine, and nifedipine in the calcium channel blockers) 
were considered interchangeable. Based on the evidence-based guideline, ACE inhibitors 
and ARB were considered a single class for this study.78 Antiplatelet agents did not 
include aspirin because aspirin is usually purchased without a prescription (over-the-
counter) and is not included in Part D claims data. Moreover, we did not include insulin 
since the days’ supply information on this drug class is not accurate.79   
 
Using interval-based PDC approach, patients were followed continuously from 
the time they had >2 fills during a 6-month period for a drug class, to the last 6-month 
period. The numerator was defined as the number of days of medication supply between 
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the first and last prescription in a period, and the denominator was defined as the number 
of days during the interval from the index date to the last day of that period. For the 
numerator, if the days’ supply extended into the next period, it contributed to both 
periods. For the denominator, we used the first day of medication fill as index date only if 
patients had >2 fill for a drug class for the first time in a period. If patients filled >2 
medications for a drug class in any of the previous periods, we considered denominator 
as 180 days. Additionally, we subtracted the inpatient days from the denominator. The 
average PDC measure was calculated at the patient-level by adding the PDC for each 
drug class and then dividing by the number of drug class used by the patient. Patients 
were then classified as nonadherent if they had PDC<80% over the 6-month period. 
Adherence was also measured based on therapy-specific medication adherence 
classifications, which included diabetes, cardiovascular, and COPD/asthma medications. 
Additionally, as a sensitivity analysis, we measured adherence by changing the fill 
criteria of >2 medication fills for a drug class to >1 medication fill. 
 
Other covariates 
 
In addition to the primary adherence variable, we assessed mental illness, 
substance use disorder, and opioid medication use for each 6-month period. We identified 
patients with mental illness if they had a diagnosis of depression or anxiety (at least 1 
diagnosis claim present in Medicare inpatient, outpatient, or Part B claims) or >1 
anxiolytic or antidepressant fill. Opioid medication use was based on number of opioid 
medication fill (0 fill, 1 fill, 2-3 fills, >3 fills). Additionally, we identified patients with 
substance use disorder if they had a diagnosis of tobacco use disorder. 
 
Sociodemographic variables were assessed using Medicare beneficiary summary 
files. Factors assessed at baseline included age, gender, race/ethnicity, disability status, 
and end-stage renal disease (ESRD) status. Disability was not included in the multivariate 
models since everyone <65 years of age was also disabled. Additionally, ESRD was not 
included in the models since Charlson comorbidity index includes ESRD. Other 
sociodemographic factors measured for each 6-month period included whether patients 
were fully or partially eligible as dual beneficiaries in >1 month and whether patients 
received low-income cost sharing subsidy (LICS) for the index drug classes. Since the 
income threshold for receiving LICS is higher than to be eligible for Tennessee Medicaid, 
we combined them to create a variable with 3 mutually exclusive groups (non-dual non-
LICS, non-dual LICS, and dual LICS).  
 
To control for the presence of other diseases, we used the ICD-9 diagnosis codes 
present on at least 1 Medicare inpatient, outpatient, or Part B claim, to identify patients in 
each 6-month period having comorbidities. Overall comorbidity was measured using the 
University of Manitoba SAS Macro for Charlson comorbidity index.80 Other control 
variables assessed for each 6-month period included >1 physician office visits, number of 
unique medications filled, and number of unique prescribers. 
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Statistical Analysis 
 
For multivariate analyses, we pooled observations from the four 6-month periods. 
The unit of analysis was patient-period. The viability of using a random effects model or 
a fixed effects model was tested using the Hausman specification test.93 For both 
outcomes, the null hypothesis was rejected (P<0.01) indicating that a fixed effects model 
would be superior to account for potential endogeneity that arises if an unobserved 
characteristic is related to both the independent variables and the outcome. One such bias 
is known as ‘healthy user effect’—people who are adherent to their medications also 
engage in health-enhancing behavior and are different from nonadherent individuals.94 
Thus, we used fixed effects negative binomial model at the patient level to control for this 
potential problem. We estimated separate models for each age group (i.e., <65 and >65 
years) to understand associations specific to these Medicare age groups. We included 
lagged effects of all independent factors in the models.  
 
In addition to the main models, we also conducted multivariate fixed effects 
analyses to examine the association between medication nonadherence and inpatient and 
ED utilization across different therapy classes—diabetes, cardiovascular, and 
COPD/asthma medication class. Additionally, to investigate the association between 
time-invariant factors including race, dual LICS status and inpatient and ED utilization, 
we conducted a random effects model. As sensitivity analyses, we ran models by 
changing the adherence measure criteria of >2 medication fills to >1 fill. All data 
analyses were conducted using SAS 9.4 and STATA 13. Variables in the multivariate 
models with P<0.05 were considered significant. 
 
 
RESULTS 
 
Characteristics of the study subjects (N=1,092) in each 6-month evaluation period 
are shown in Table 3-1. The mean age for the study population was 65.1, and 43.0% 
were <65 years of age. The study subjects were predominantly female (58.8%), non-
Hispanic black (68.6), dual eligible (63.7%), and received LICS (68.7%). In the fourth 
period, which was the qualifying period for the SafeMed Program, patients had a mean of 
3.1 (0.9) inpatient stays and 1.7 (2.6) ED visits, which was higher than previous periods. 
Additionally, in the same period, 97.2% of patients had >2 chronic conditions, 57.0% had 
mental illness, and 69.0% filled >1 opioid medications. The patterns of medication 
adherence among the study subjects during each 6-month evaluation period is shown in 
Figure 3-1. The mean PDC for patients decreased progressively from period 1 to period 
4; mean PDC was 80.3% in period 1 and declined to 63.0% in period 4. Using the 80% 
PDC cutoff, we found overall nonadherence rates for all essential drug classes in the four 
periods to be 43.2%, 56.1%, 65.5%, and 72 8%, respectively (data not shown). 
 
Table 3-2 displays results for the multivariate associations between medication 
nonadherence and inpatient stays and ED visits by therapy class, using fixed effects 
negative binomial models. For the three therapy classes displayed — diabetes, 
cardiovascular, and COPD/asthma — the adjusted models indicated that the incidence of 
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Table 3-1. Characteristics of SafeMed Eligible Patients in Each 6-Month Patient-Period (N=1,092) 
 
Characteristics Period 1 Period 2 Period 3 Period 4 
 N (%) N (%) N (%) N (%) 
Age 
<65 years 
>65 years 
mean age (SD) 
 
468 (42.9) 
624 (57.1) 
65.1 (14.5) 
 
- 
 
 
 
- 
 
- 
 
Female 642 (58.8) - - - 
Race/Ethnicity 
Non-Hispanic white 
Non-Hispanic black 
Other 
 
326 (29.9) 
749 (68.6) 
17 (1.6) 
 
- 
 
- 
 
 
- 
 
 
Eligibility status 
Disabled 
End-stage renal disease 
Dual eligible 
Receiving low-income cost sharing subsidy 
 
407 (37.3) 
324 (29.7) 
696 (63.7) 
750 (68.7) 
 
- 
- 
694 (63.6) 
790 (72.3) 
 
- 
- 
697 (63.8) 
791 (72.4) 
 
- 
- 
692 (63.4) 
803 (73.5) 
Qualifying Chronic Conditions 
Diagnosis of Hypertension 
Diagnosis of Diabetes 
Diagnosis of Congestive heart failure 
Diagnosis of Coronary artery disease 
Diagnosis of Asthma 
Diagnosis of Chronic obstructive pulmonary disease 
Number of qualifying chronic conditions 
<1 chronic conditions 
2 chronic conditions 
3 chronic conditions 
4 or more chronic conditions 
 
852 (78.0) 
571 (52.3) 
338 (31.0) 
368 (33.7) 
134 (12.3) 
246 (22.7) 
 
335 (30.82) 
262 (24.0) 
247 (22.6) 
246 (22.5) 
 
950 (87.0) 
638 (58.4) 
467 (42.8) 
481 (44.1) 
199 (18.2) 
343 (31.4) 
 
226 (20.7) 
236 (21.6) 
244 (22.3) 
386 (35.3) 
 
1,028 (94.1) 
696 (63.7) 
603 (55.2) 
590 (54.0) 
262 (24.0) 
448 (41.0) 
 
131 (12.0) 
204 (18.7) 
250 (23.0) 
507 (46.4) 
 
1,086 (99.5) 
784 (71.8) 
799 (73.2) 
785 (71.9) 
377 (34.5) 
583 (53.4) 
 
31 (2.8) 
115 (10.5) 
211 (19.3) 
735 (67.2) 
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Table 3-1. Continued 
 
Characteristics Period 1 Period 2 Period 3 Period 4 
 N (%) N (%) N (%) N (%) 
Comorbidity 
Charlson comorbidity index, mean (SD) 
Mental illness* 
Tobacco use disorder 
 
3.2 (2.7) 
389 (35.6) 
106 (9.7) 
 
4.2 (3.1) 
460 (42.1) 
163 (14.9) 
 
5.2 (3.3) 
533 (48.8) 
266 (24.4) 
 
6.9 (3.2) 
622 (57.0) 
351 (32.1) 
Therapy complexity 
No. of unique index drug classes filled, mean (SD) 
No. of opioids filled, mean (SD) 
0 opioid filled   
1 opioid filled 
2-3 opioid filled 
>4 opioid filled 
 
3.9 (2.1) 
2.6 (4.0) 
499 (45.7) 
147 (13.5) 
159 (14.6) 
287 (26.3) 
 
4.0 (2.1) 
2.7 (4.0) 
479 (43.9) 
165 (15.1) 
143 (13.1) 
305 (27.9) 
 
3.9 (2.1) 
2.7 (3.9) 
480 (44.0) 
157 (14.4) 
151 (13.8) 
304 (27.8) 
 
4.3 (2.0) 
3.2 (4.1) 
337 (31.0) 
187 (17.1) 
211 (19.3) 
357 (32.7) 
Health services utilization 
≥1 physician office visits 
No. of inpatient stays, mean (SD) 
No. of emergency department visits, mean (SD) 
Super-utilizers 
 
900 (82.4) 
0.8 (1.4) 
0.8 (2.1) 
168 (15.4) 
 
903 (82.7) 
0.8 (1.4) 
0.8 (2.2) 
187 (17.1) 
 
909 (83.2) 
0.7 (1.4) 
0.9 (2.2) 
155 (14.2) 
 
915 (83.8) 
3.1 (0.9) 
1.7 (2.6) 
1,192 (100.0) 
 
Physician office visits were identified using Part B claims and were defined as “location, other than a hospital, skilled nursing facility 
(SNF), military treatment facility, community health center, State or local public health clinic, or intermediate care facility (ICF), 
where the health professional routinely provides health examinations, diagnosis, and treatment of illness or injury on an ambulatory 
basis.” *Mental illness was defined as >1 antidepressants or anxiolytics fill or diagnosis of depression/anxiety. Super-utilizers defined 
as >3 inpatient admissions OR >2 inpatient admissions and >2 emergency department visits in 6 months. 
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Figure 3-1. Proportion of Days Covered (PDC) During Each 6-Month Period 
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Table 3-2. Multivariable Results for Inpatient Stays and Emergency Department 
Visits by Therapy Class Using Fixed Effects Model 
 
 Inpatient Stays    ED Visits 
Therapy Class IRR (95% CI) P Value  IRR (95% CI) P Value 
Diabetes Medications 
Nonadherence (overall sample) 
Nonadherence (<65 years) 
Nonadherence (>65 years) 
 
1.22 (1.02-1.45) 
0.97 (0.72-1.30) 
1.38 (1.11-1.72) 
 
0.026 
0.823 
0.004 
  
1.17 (0.95-1.45) 
1.23 (0.86-1.75) 
1.16 (0.89-1.52) 
 
0.132 
0.256 
0.266 
Cardiovascular Disease Medications 
Nonadherence (overall sample) 
Nonadherence (<65 years) 
Nonadherence (>65 years) 
 
1.42 (1.25-1.61) 
1.35 (1.13-1.62) 
1.42 (1.19-1.69) 
 
<0.001 
0.001 
<0.001 
  
1.14 (0.99-1.31) 
1.23 (1.02-1.49) 
1.05 (0.86-1.29) 
 
0.070 
0.033 
0.622 
COPD or Asthma Medications 
Nonadherence (overall sample) 
Nonadherence (<65 years) 
Nonadherence (>65 years) 
 
1.35 (1.00-1.82) 
1.07 (0.66-1.73) 
1.48 (1.01-2.18) 
 
0.048 
0.781 
0.047 
  
1.24 (0.87-1.75) 
1.21 (0.77-1.91) 
1.11 (0.65-1.89) 
 
0.237 
0.403 
0.712 
 
Significant at P<0.05. IRR: Incidence Rate Ratio. ED Visits: Emergency department 
visits. COPD: Chronic Obstructive Pulmonary Disease. 
We used fixed effects negative binomial models at patient level. The adjusted models 
included lagged effects of medication nonadherence, Charlson comorbidity index, mental 
illness, opioid medication filled, number of medications filled, number of different 
prescribers, and >1 physician office visits.  
Mental illness was defined as >1 antidepressants or anxiolytics fill or diagnosis of 
depression/anxiety.  
Diabetes Medications: Sample for inpatient stays - nonadherence (overall): 855 patient-
periods, nonadherence (<65 years): 312 patient-periods, nonadherence (>65 years): 543 
patient-periods. 
Sample for ED visits – nonadherence (overall): 624 patient-periods, nonadherence (<65 
years): 251 patient-periods, nonadherence (>65 years): 373 patient-periods. 
Cardiovascular Disease Medications: Sample for inpatient stays – nonadherence 
(overall): 2,893 patient-periods, nonadherence (<65 years): 1,177 patient-periods, 
nonadherence (>65 years): 1,716 patient-periods. 
Sample for ED visits – nonadherence (overall): 2,133 patient-periods, nonadherence (<65 
years): 945 patient-periods, nonadherence (>65 years): 1,188 patient-periods. 
COPD or Asthma Medications: Sample for inpatient stays – nonadherence (overall): 513 
patient-periods, nonadherence (<65 years): 209 patient-periods, nonadherence (>65 
years): 304 patient-periods. 
Sample for ED visits – nonadherence (overall): 359 patient-periods, nonadherence (<65 
years): 158 patient-periods, nonadherence (>65 years): 201 patient-periods. 
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inpatient stays was higher for nonadherent patients (P<0.05) compared with adherent 
patients. In the overall sample, the number of inpatient stays were 22% higher in patients 
not adherent to their diabetes medications (Incidence Rate Ratio (IRR), 1.22; Confidence 
Interval (CI), 1.02-1.45; P=0.026), 42% higher in patients who were nonadherent to their 
cardiovascular disease medications (IRR, 1.42; CI, 1.25-1.61; P<0.001), and 35% higher 
in patients not adherent to their COPD/asthma medications (IRR, 1.35; CI, 1.00-1.82; 
P=0.048). Additionally, the adjusted analyses for ED visits showed that in the overall 
sample, nonadherence to essential chronic medications was not significantly associated 
with ED visits (P<0.05). When examining the results stratified by age, we found that the 
association between nonadherence to CVD medications and inpatient admissions was 
significant for both age groups. Whereas for diabetes and COPD/asthma therapy classes, 
the association with inpatient admissions was significant only among elderly Medicare 
beneficiaries. Additionally, the association between nonadherence to CVD medications 
and ED visits was significant for non-elderly Medicare patients.  
 
Table 3-3 shows the multivariate associations among Medicare beneficiaries >65 
years of age. Patients who were nonadherent to their essential chronic medications had 
57% higher inpatient stays (IRR, 1.57; CI, 1.33-1.87; P<0.001) compared with adherent 
patients. The association between medication nonadherence and ED visits was not 
statistically significant. Among other factors, mental illness was associated with 54% 
higher inpatient stays (IRR, 1.54; CI, 1.20-1.98; P=0.001) and 46% higher ED visits 
(IRR, 1.46; CI, 1.11-1.93; P=0.007). Opioid medication fills in the previous period were 
protective against inpatient and ED utilization among elderly Medicare beneficiaries, 
however, these associations were not statistically significant.  
 
Table 3-4 displays the same results among Medicare beneficiaries <65 years of 
age. Patients who were nonadherent to their essential chronic medications had 41% 
higher inpatient stays (IRR, 1.41; CI, 1.17-1.69; P<0.001) and 25% higher ED visits 
(IRR, 1.25; CI, 1.04-1.51; P=0.020) compared with adherent patients. Mental illness was 
not significantly associated inpatient and ED use, while tobacco use disorder was 
significantly associated with higher inpatient utilization (IRR, 1.61; CI, 1.17-2.22; 
P=0.003). Additionally, among non-elderly Medicare beneficiaries, opioid medication 
use in the previous period was not significantly associated with inpatient and ED use. 
 
When examining the association between race and dual-LICS status with inpatient 
and ED visits (Appendix B, Tables B-1 and B-2), random effects models showed that 
among elderly Medicare beneficiaries, non-Hispanic blacks had significantly higher ED 
use, and dual eligible beneficiaries with LICS had significantly higher inpatient and ED 
utilization. Similarly, among non-elderly Medicare beneficiaries, dual beneficiaries with 
LICS had significantly higher ED utilization. In sensitivity analyses using the alternative 
PDC criteria of >1 medication fill, our results were similar in terms of significance and 
directionality to our main analyses (Appendix B, Tables B-3 and B-4). 
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Table 3-3. Multivariable Results for Inpatient Stays and Emergency Department 
Visits Among Medicare Beneficiaries ≥65 years 
 
Characteristics Inpatient Stays    ED Visits 
 IRR (95% CI) P Value  IRR (95% CI) P Value 
Overall medication nonadherence 1.57 (1.33-1.87) <0.001  1.11 (0.91-1.34) 0.308 
Comorbidity 
Charlson comorbidity index 
Mental illness 
Tobacco use disorder  
 
1.23 (1.17-1.28) 
1.54 (1.20-1.98) 
1.29 (0.90-1.84) 
 
<0.001 
0.001 
0.166 
  
1.16 (1.09-1.23) 
1.46 (1.11-1.93) 
0.79 (0.50-1.25) 
 
<0.001 
0.007 
0.309 
Opioid medication filled 
0 opioid fill (ref) 
1 opioid fill 
2-3 opioid fill 
>3 opioid fill 
Number of unique medications 
filled 
 
-- 
0.96 (0.77-1.20) 
0.86 (0.66-1.11) 
0.87 (0.64-1.18) 
1.02 (0.99-1.05) 
 
-- 
0.726 
0.248 
0.380 
0.136 
 
  
-- 
0.92 (0.72-1.17) 
0.90 (0.68-1.18) 
0.77 (0.54-1.11) 
0.97 (0.94-1.07) 
 
-- 
0.487 
0.448 
0.161 
0.106 
Number of unique prescribers 0.97 (0.92-1.02) 0.176  0.98 (0.93-1.04) 0.512 
>1 physician office visit  0.91 (0.67-1.23) 0.532  1.64 (1.00-2.69) 0.051 
 
Significant at P<0.05. IRR: Incidence Rate Ratio. ED visits: Emergency department 
visits. 
We used fixed effects negative binomial models at patient level. The models included 
lagged effects of all the above factors.  
Overall medication nonadherence measured at patient-level was based on eighteen index 
drug classes. 
Mental illness is defined as >1 antidepressants or anxiolytics fill or diagnosis of 
depression/anxiety.  
The multivariable model with inpatient stays as outcome included 1,742 patient-periods. 
The multivariable model with ED visits as outcome included 1,203 patient-periods. 
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Table 3-4. Multivariable Results for Inpatient Stays and Emergency Department 
Visits Among Medicare Beneficiaries <65 years 
 
Characteristics Inpatient Stays  ED Visits 
 IRR (95% CI) P Value  IRR (95% CI) P Value 
Overall medication nonadherence 1.41 (1.17-1.69) <0.001  1.25 (1.04-1.51) 0.020 
Comorbidity 
Charlson comorbidity index 
Mental illness 
Tobacco use disorder  
 
1.18 (1.13-1.23) 
1.14 (0.86-1.50) 
1.61 (1.17-2.22) 
 
<0.001 
0.358 
0.003 
  
1.11 (1.05-1.16) 
1.18 (0.88-1.58) 
1.30 (0.92-1.82) 
 
<0.001 
0.277 
0.135 
Opioid medication filled 
0 opioid fill (ref) 
1 opioid fill 
2-3 opioid fill 
>3 opioid fill 
Number of unique medications 
filled 
 
-- 
0.81 (0.63-1.06) 
0.83 (0.63-1.09) 
0.96 (0.69-1.33) 
1.01 (0.98-1.04) 
 
-- 
0.124 
0.182 
0.801 
0.518 
  
-- 
0.93 (0.70-1.24) 
0.98 (0.72-1.31) 
1.25 (0.87-1.79) 
1.02 (0.99-1.04) 
 
-- 
0.614 
0.873 
0.230 
0.263 
Number of unique prescribers 0.98 (0.95-1.02) 0.365  0.98 (0.95-1.02) 0.315 
>1 physician office visit  0.90 (0.67-1.20) 0.454  0.97 (0.67-1.40) 0.857 
 
Significant at P<0.05. IRR: Incidence Rate Ratio. ED visits: Emergency department 
visits 
We used fixed effects negative binomial models at patient level. The models included 
lagged effects of all the above factors.  
Overall medication nonadherence measured at patient-level was based on eighteen index 
drug classes. 
Mental illness is defined as >1 antidepressants or anxiolytics fill or diagnosis of 
depression/anxiety.  
The multivariable model with inpatient stays as outcome included 1,227 patient-periods. 
The multivariable model with emergency department visits as outcome included 986 
patient-periods. 
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DISCUSSION 
 
This study is the first, to our knowledge, to examine the relationship between 
nonadherence, and other important factors with health care utilization in super-utilizers 
with chronic conditions. In our sample of super-utilizing Medicare population with 
chronic conditions, we found higher incidences of inpatient hospitalizations and ED visits 
among beneficiaries who were not adherent to their essential chronic medications. 
Specifically, we found that among elderly Medicare beneficiaries, nonadherence was 
significantly associated with a 57% increase in inpatient hospitalizations, and among 
younger beneficiaries, nonadherence was associated with 41% increase in inpatient stays 
and 25% increase in ED visits. Similar associations were found across all therapy classes 
examined (diabetes, cardiovascular, and COPD/asthma) in both age groups. However, 
nonadherence to diabetes and COPD/asthma drugs was not significantly associated with 
ED visits. Furthermore, we found that while the effects of nonadherence on inpatient 
stays were seen in both age groups, the effects of nonadherence on ED visits were more 
pronounced for younger Medicare patients. These findings suggest that nonelderly 
Medicare beneficiaries may be at increased risk for nonadherence which may further be 
associated with higher ED use. Targeted medication management interventions for 
younger Medicare beneficiaries may potentially help in lowering their ED visits.  
 
Our results provide important insights into associations between medication 
nonadherence and hospitalizations and are consistent with prior research on Medicare 
population which showed nonadherence to be associated with higher incidence of 
hospitalizations. Simoni-Wastila and colleagues found that Medicare patients with COPD 
who were adherent to their chronic medications experienced fewer hospitalizations.6 And 
in a sample of Medicare patients with myocardial infarction, Zhang and colleagues found 
that higher adherence with β-blockers, statins, and ACEIs/ARBs medications was 
associated with lower readmission rates.39 However, unlike previous studies based on 
Medicare population, this study focused specifically on super-utilizing Medicare patients 
with chronic conditions. Moreover, our study population was disproportionately 
represented by dual beneficiaries <65 years of age, who had on average higher 
comorbidities and were more likely to be nonadherent to their essential chronic 
medications than elderly patients. Given these differences, examining associations 
separately in the two age groups may help researchers to better target these high utilizing 
patient populations with medication management interventions. Our work extends these 
findings to these vulnerable patients and suggests that improving medication adherence—
a patient behavioral factor very amenable to change—may be critical in reducing 
inpatient and ED utilization among Medicare super-utilizers with chronic conditions and 
complex pharmacotherapy regimens. 
 
This analysis reinforced our previous findings that the super-utilizer status is 
dynamic and changes with time.56,57 We found that of 1,092 patients who met the super-
utilizers criteria in the fourth period (qualifying period for the SafeMed Program), only 
about 14% of them were super-utilizers in all previous periods (Table 3-1). The higher 
rates of inpatient and ED utilization and lower rates of medication adherence in the last 6-
month period compared to the first three periods, indicate a sudden change in adherence 
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and utilization in the final period. Providing early medication management interventions 
to potential high-risk super-utilizers may improve adherence thereby lowering their 
inpatient and ED utilization.  
 
Similar to previous findings in super-utilizing population, we found high rates of 
mental illness and substance use disorder in super-utilizers56,58 — about 57% were 
diagnosed with depression or anxiety or had filled antidepressants or anxiolytics and 32% 
were diagnosed with substance use disorder, in the fourth period. In our adjusted models, 
we found mental illness as a risk factor for higher utilization among elderly, and 
substance use disorder as a risk factor for higher inpatient utilization among younger 
patients. These findings may help to identify and classify high-risk super-utilizers who 
need targeted medication management interventions along with mental health and social 
support.  
 
This study makes a significant contribution to the body of empirical literature on 
super-utilizers by demonstrating high opioid use in this population. Specifically, we 
found that about 69% had filled >1 opioid medications in the fourth period. A substantial 
amount of opioid utilization is likely driven by the high prevalence of chronic pain in the 
super-utilizers as documented in a previous study.57 In our adjusted models, although 
insignificant, we found that super-utilizers with recent opioids use make less use of ED 
and inpatient services, especially among elderly Medicare patients. A recent study found 
that opioid use is common after hospitalization among Medicare beneficiaries.92 Future 
studies should investigate the reasons behind this finding as this can shed some light on 
the patterns of high opioid use in this population. 
 
Among other factors, non-Hispanic blacks and dual beneficiaries receiving LICS 
were at risk for higher utilization. These findings are consistent with previous studies 
conducted on Medicare patients.95,96 For instance, Joynt and colleagues examined racial 
disparities in readmissions among elderly Medicare beneficiaries and found that black 
patients were more likely to be readmitted after hospitalization for myocardial infarction, 
congestive heart failure, and pneumonia.96 Furthermore, it has been well established that 
dual beneficiaries have higher utilization and account for disproportionate share of 
Medicare spending. Our findings highlight the vulnerability of these groups and the need 
for greater attention. 
 
This study has important implications for policy makers and institutions involved 
in improving the quality of care and reducing health care costs for super-utilizers. Our 
study findings suggest that improving medication adherence may be critical in reducing 
inpatient and ED use. Given these findings, hospitals, managed care organizations, and 
payers should engage in programs aimed at improving medication adherence in super-
utilizing population. Successful medication management interventions have used multiple 
strategies, including pharmacist-provided medication therapy management, specialized 
medication packaging, motivational strategies, and telemonitoring, among others.1,40,43,44 
However, targeting interventions to patients with multiple chronic conditions, complex 
medication regimens, and high health care utilization, needs a comprehensive multimodal 
approach that can address patient and system-level barriers to achieving optimal 
 44 
medication adherence. In our prior work, we found that during care transitions processes 
from the hospital to the community setting, super-utilizers were at high risk for drug 
therapy problems and medication discrepancies, which may result in poor adherence.13 
This cyclical process of nonadherence leading to increased frequency of hospitalizations, 
causing drug therapy problems and medication discrepancies in super-utilizers, can have 
detrimental effects on their health outcomes. Our findings showing high prevalence of 
mental illness, substance use disorder, and opioid medication use have highlighted the 
importance of monitoring for signs of opioid abuse, and having a strong social support 
and mental health facilities for vulnerable super-utilizing populations who have complex 
medical and social needs. Patients with complex behavioral health issues could benefit 
from greater coordination of health care providers and health care systems and having 
access to high-quality mental health services. 
 
Our study is also subject to several limitations. First, although pharmacy fill data 
is widely used to assess medication adherence, we cannot be certain that patients who fill 
medications are also using them appropriately. Second, many patients may have been 
long-term users of essential chronic medications, and we may have missed a few if they 
did not have any medication fill during the 2-year evaluation period. Third, the PDC 
measure for calculating adherence is an indirect method and may not accurately capture 
medication use and is likely to be biased for inhalation products that are prescribed for 
Asthma and COPD. Fourth, since this study is based on super-utilizers living in 
Memphis, TN, the study findings may only be generalizable to similar populations and 
similar settings across the country. Finally, although our fixed-effects models addressed 
potential endogeneity, we cannot conclude with certainty that these associations were 
causal. 
 
 
CONCLUSION 
 
In summary, medication nonadherence was associated with increased incidence of 
hospitalizations and ED use, both overall and across diabetes, cardiovascular, and 
COPD/asthma therapy classes. Additionally, the effects of nonadherence on ED visits 
were more pronounced for younger Medicare beneficiaries. Among other important 
factors, mental illness, tobacco use disorder, non-Hispanic black race, and dual eligible 
beneficiaries with low-income subsidy predicted higher inpatient and ED use. 
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CHAPTER 4.    EFFECT OF A CARE TRANSITIONS PROGRAM ON 
MEDICATION USE AND ADHERENCE AMONG SUPER-UTILIZERS WITH 
CHRONIC CONDITIONS 
 
 
BACKGROUND 
 
Super-utilizers are patients who have high health care costs from recurring, 
preventable inpatient or emergency department (ED) visits. A decade ago Dr. Jeffrey 
Brenner, a physician from Camden, NJ, had identified that a small group of patients 
accounted for a bulk of health care costs.55 Since then the interest in super-utilizers has 
increased among policymakers, health systems, and researchers. Super-utilizers represent 
only 3 to 10% of Medicare and Medicaid population, but are responsible for 30 to 50% of 
the health care spending.56 They often face complex medical and social issues including 
multiple chronic conditions (MCC), mental health illnesses, substance abuse, issues with 
transportation, low health literacy, and low social support, among others.56-58 During care 
transitions processes, super-utilizers often experience difficulty in medication 
management; medication discrepancies and drug therapy problems being key factors in 
making these care transitions complex.13,18,97. Managing medication-related adverse 
events and improving medication adherence among super-utilizers may be critical for 
hospitals and payers since improving adherence to essential chronic medications is 
crucial for reducing preventable hospital readmissions.4,5,39 Given the widespread 
recognition that drug therapy problems and medication nonadherence play a major role in 
readmissions, care transitions models with a focus on medication management are being 
increasingly explored to reduce drug therapy problems and improve medication 
adherence.17,19,54 
 
Pharmacists can play a central role in care transitions models focused on 
medication management. To date, studies evaluating the impact of pharmacist-led 
interventions on medication errors, medication adherence, and health care utilization after 
hospital discharge have shown mixed results.17,19,49,54,98,99 For example, Kripalani and 
colleagues found that among patients hospitalized with acute coronary syndromes or 
acute decompensated heart failure, the pharmacist-led interventions did not significantly 
reduce medication errors after hospital discharge.19 Schnipper and colleagues found that 
pharmacist-provided interventions for patients discharged home from the general 
medicine service was associated with a lower rate of preventable adverse drug events 
(ADE). However, there was no significant effect of these interventions on overall ADE or 
total health care utilization.17 Another study by Ho and colleagues found that among 
patients with acute coronary syndrome, multifaceted pharmacist-led interventions 
increased adherence to cardioprotective agents one year following hospital discharge. 
Nonetheless, the intervention did not have any positive effect on blood pressure and low-
density lipoprotein cholesterol levels.49 Except for the study by Ho and colleagues, the 
interventions were mainly provided in the hospital setting. Moreover, despite increased 
interest in super-utilizers and increased focus on reducing their disproportionate health 
care utilization and costs, there is a lack of evidence on whether pharmacist-led intensive 
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medication management interventions as part of a care transitions program can improve 
medication use and adherence in super-utilizers with chronic conditions. 
 
This study was an evaluation of the SafeMed Program, an innovative care 
transitions program targeting super-utilizers with a major focus on medication 
management.60 Pharmacist-led interventions as part of the SafeMed Program included the 
following: comprehensive medication review (CMR), targeted medication therapy 
management (MTM), enhanced discharge planning, home visits, phone follow-ups, 
medication reconciliation during discharge and post-discharge, and care coordination 
with patient’s physicians.13 The objective of this study was to examine the impact of the 
SafeMed Program on medication utilization and adherence among a vulnerable, publicly 
insured, super-utilizing cohort of patients admitted to a local hospital system in Memphis, 
TN. The study findings may have a positive impact by highlighting the importance of 
innovative care transitions medication management interventions that can improve 
adherence among vulnerable super-utilizers, who can benefit the most from such 
interventions. 
 
 
METHODS 
 
 
Design and Setting 
 
This study used a quasi-experimental study design to examine the effectiveness of 
the SafeMed Program on medication adherence among SafeMed participants compared 
with patients in a control group using difference in differences (DID) approach. The 
SafeMed program targeted publicly insured super-utilizers with chronic conditions from 
medically underserved areas admitted to a non-profit hospital system in Memphis, TN 
from February 1, 2013 to May 1, 2015.60 We analyzed Medicare and Tennessee Medicaid 
claims data for this study. We had Tennessee Medicaid claims data for beneficiaries 
meeting the SafeMed Program eligibility criteria for the entire program duration—from 
February 1, 2013 to May 1, 2015. However, since the Medicare Part D data files were 
incomplete at the time of this study, we used Medicare claims data only for the period 
from February 1, 2013 to June 30, 2014. The program enrollment occurred during an 
inpatient admission or an observation stay (index admission), after which the patients 
who agreed to participate in the SafeMed Program were provided the various medication 
management interventions for a minimum of 45 days following hospital discharge. For 
this study evaluation, program participants and controls were followed for 6-month post 
index discharge and 6 months prior to their index admission.  
 
 
Population 
 
The SafeMed Program eligibility was based on the following inclusion criteria: 1) 
adults aged 18 years or older with continuous Medicare or Medicaid enrollment, 2) >2 
hospital admissions in the past six months OR 1 inpatient admission and >2 emergency 
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department (ED) visits in the six months prior to the index admission, and 3) diagnosis of 
>1 of the following chronic conditions: hypertension, congestive heart failure (CHF), 
coronary artery disease (CAD), diabetes mellitus, asthma, or chronic obstructive 
pulmonary disease (COPD) in the baseline period. The International Classification of 
Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes for the inclusion 
criteria are listed in Appendix A, Table A-1.  
 
Patients were excluded from the SafeMed Program if the primary reason for index 
admission was related to cancer, pregnancy, or a surgical procedure for an acute problem 
following the approach of Jencks and colleagues recognizing that utilization for these 
conditions is less likely to be affected by outpatient chronic disease care or medication 
management.77 Patients were also excluded if they had diagnoses of active psychosis, 
drug abuse, substance abuse or suicidal ideation during the index admission, or if they 
were discharged to a skilled nursing facility or hospice care because of evidence 
suggesting that high utilization in these patient populations may be less amenable to 
outpatient intervention.57 The ICD-9-CM codes and diagnosis-related group (DRG) codes 
for the exclusion criteria are listed in a previous paper by Harris and colleagues.57 
 
The control group included patients deemed eligible for the SafeMed Program 
based on the eligibility criteria listed above, but who either: 1) declined to participate in 
the program when they were offered the chance to participate, or 2) were discharged from 
the hospital before the SafeMed staff had an opportunity to screen them and offer 
participation, or 3) met basic SafeMed eligibility requirements based on a daily eligibility 
report generated by the hospital system. We used Medicare and Medicaid claims data to 
confirm further their eligibility based on the inclusion and exclusion criteria. 
 
Of the 1,778 eligible patients meeting SafeMed inclusion and exclusion criteria 
above, the final sample included the 1,122 (63.1%) who were continuously eligible for 
Medicare Part D or had drug coverage from Medicaid and filled at least one of seventeen 
drug classes during both pre-and post-periods. These drug classes included angiotensin-
converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB), statins, 
antiplatelet agents, beta-blockers, calcium channel blockers, diuretics, alpha-1 blockers, 
central alpha-2 agonists, direct vasodilators, sulfonylureas, biguanides, 
thiazolidinediones, meglitinides, dipeptidyl peptidase-4 inhibitors, anticholinergic 
inhalers, inhaled corticosteroids alone or in combination with long-acting beta-agonists 
(LABA), and other COPD/asthma medications (theophylline and leukotriene modifiers). 
 
 
Program Description 
 
The program used a diverse team of health care providers, including pharmacists 
and pharmacy technicians as key team members. The SafeMed medication management 
team, including two program pharmacists and two certified pharmacy technicians, 
worked together to provide medication management services to SafeMed enrollees. As 
previously described, patient enrollment occurred during an inpatient admission or an 
observation stay, during which the SafeMed enrollees received an inpatient CMR from 
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the pharmacists. SafeMed pharmacists reviewed the drug profile with patients or their 
caregivers to identify any drug therapy problems. They made appropriate 
recommendations and worked closely with the physicians and alerted them of the 
identified drug therapy problems. Additionally, as part of the discharge planning, 
pharmacists provided and discussed a personalized patient-friendly medication list with 
patients, explained the purpose of each medication, dosing instructions, and potential side 
effects. The role of the pharmacy technician was to identify any potential drug therapy 
problems during home visits and phone follow-ups, who then coordinated with the 
pharmacist to resolve any medication-related issues. 
 
Medication reconciliation, which involved comparing patient’s discharge 
medication orders to all the medications that the patient had been taking, was performed 
by pharmacy technicians during the first and second home visits that happened within 3 
days and 3 weeks of discharge, respectively. This ensured that any omissions, 
duplications, potential drug interactions, or any potential dosing errors and adverse events 
were identified and reported to the pharmacist. During home visits, pharmacy technicians 
also educated patients on drug disposal, filling pill boxes, and self-management 
guidelines. A minimum of two phone follow-ups were performed during the second and 
the fourth week of discharge. During each phone follow-up, pharmacy technicians 
identified barriers to using any prescribed medications and potential drug therapy 
problems. Pharmacists then followed-up with patients who were identified as having drug 
therapy problems and provided targeted MTM by phone and outpatient CMR to further 
resolve any medication-related issues and to improve the overall effectiveness of their 
medication regimen. Follow-up outpatient CMR was provided to patients during the fifth 
week of the SafeMed Program, after the completion of home visits and phone follow-ups 
by pharmacy technicians. The overall interventions including pharmacist-led medication 
management interventions provided at different time points have been shown in 
Appendix C, Table C-1.76  
 
 
Outcome Variables 
 
Medication adherence 
 
Medication adherence was measured using the interval-based proportion of days 
covered (PDC), defined as the percentage of days during the observation period during 
which the participants or controls had their recommended prescribed medications on 
hand. PDC was expressed as percentage capped at 100% and was calculated for the 6-
month baseline period and the 6-month evaluation period. We measured PDC for the 
seventeen drug classes mentioned above. Drugs that belonged to the same therapeutic 
class (example, amlodipine, and nifedipine in the calcium channel blockers) were 
considered interchangeable. Additionally, based on the evidence-based guideline, ACE 
inhibitors and ARB were considered a single class for this study.78 Antiplatelet agents did 
not include aspirins because aspirins are usually purchased without a prescription (over-
the-counter) and are not included in Part D claims data. Moreover, we did not include 
insulin since the days’ supply information on this drug class is not accurate.79 
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Using this approach, the numerator was defined as the number of days of 
medication supplied between the first and last prescription in a period and the 
denominator was defined as the number of days during the interval from the index date, 
which was the first day of the medication fill in a given 6-month period, to the last day of 
that period. Any duration of inpatient hospitalization was subtracted from the PDC 
denominator. The average PDC measure was calculated at the patient-level by adding the 
PDC for each drug class and then dividing by the number of drug class used by the 
patient. We then classified patients as adherent if they had PDC of at least 80% over the 
follow-up and pre-intervention period. The main outcome variable was the overall binary 
adherence classification. Adherence was also measured based on therapy-specific 
medication adherence classifications, which included diabetes, cardiovascular, and 
COPD/asthma medications. Additionally, PDC was measured in the patient sample 
stratified by age, insurance type and number of comorbidities. 
 
Medication use 
 
We also examined whether the intervention had any positive effect on medication 
use based on a patient’s diagnosis. Following were the medication use measures: 1) 
patients diagnosed with diabetes using any oral diabetes medications, 2) patients 
diagnosed with COPD or asthma using any long-term controller medications, and 3) 
patients diagnosed with CHF using any ACE/ARB medications. 
 
 
Independent Variables 
 
The main independent variables included a binary indicator of whether patients 
received the SafeMed intervention (1=Participant, 0=Control) and a binary indicator of 
time (1=post-intervention period, 0=pre-intervention period). Additionally, the 
multivariate models controlled for the following covariates: age, gender, race, and 
insurance, measured at the index admission. Covariates assessed for the 6-month baseline 
period included diagnosis of depression or anxiety, and disease burden measured using 
the University of Manitoba SAS Macro for Charlson comorbidity index.80 
 
 
Statistical Analysis 
 
Propensity score matching was conducted to account for the observed differences 
between the intervention and the control group. The propensity score, which was 
estimated using a logistic regression model, was defined as the patient’s probability of 
receiving the SafeMed intervention versus no intervention and was conditional on the 
measured baseline covariates that included age, gender, race, insurance, qualifying 
chronic conditions, Charlson comorbidity index, and anxiety/depression. Propensity score 
matching paired each participant of the intervention group to 2 controls within calipers of 
0.01 units on the propensity score scale.100 All analyses were conducted on propensity 
score-matched samples. Baseline differences between study participants and controls 
were estimated using chi-square tests and t-tests analyses. For multivariate analyses, we 
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used logistic regression with DID approach to estimate changes in average probability of 
adherence or medication use from the pre-intervention period to post-intervention period 
that differed from concurrent changes in the control group, after controlling for 
confounding variables. While DID models with only one pre-intervention and one post-
intervention observation cannot control for differences in time trends in the SafeMed 
enrollees and controls, it does allow us to control for permanent unobserved differences 
between the groups. All data analyses were conducted using SAS 9.4 and STATA 13. 
Variables in the multivariate models with P<0.05 were considered significant. 
 
 
RESULTS 
 
Table 4-1 provides the baseline characteristics for the SafeMed enrollees and 
controls before and after applying propensity score matching. Before propensity score 
matching, enrollees (N=152) and controls (N=970) were different on several measures. 
Compared with controls, the enrollees were more likely to be younger (52.2 vs. 59.7, 
P<0.001), black (77% vs. 68.7%, P<0.001), and Medicaid only beneficiaries (52% vs. 
32.7%, P<0.001). Additionally, compared with controls, enrollees were more likely to 
have diabetes (71.1% vs. 61.2%, P=0.020), asthma (42.1% vs. 29.5%, P=0.002), COPD 
(58.6% vs. 43.2%, P=0.004), and lower mean Charlson comorbidity index (4.4 vs. 4.8, 
P=0.042). After applying propensity score matching, although the sample size reduced 
from 1,122 to 456, the intervention (N=152) and the control group (N=304) were similar 
across all sociodemographic and clinical factors. 
 
The patterns of mean PDC among the enrollees and controls during pre- and post-
intervention periods is shown in Figure 4-1. The mean PDC was lower in enrollees than 
controls in both pre- and post-intervention periods. Additionally, the mean PDC for 
enrollees and controls decreased progressively from the pre- to the post-intervention 
period. Among enrollees, the mean PDC was 63.8% in the pre-intervention period and 
declined to 61.8% in the post-intervention period. Similarly, among controls, the mean 
PDC was 70.5% in the pre-intervention period and declined to 65.6% in the post-
intervention period. The proportion of adherent patients (PDC >80%) among enrollees 
declined from 34.2% in the pre-intervention period to 25.0% in the post-intervention 
period, while among controls, this proportion declined from 41.1% to 32.6% (results not 
shown). 
 
Table 4-2 shows the DID results for overall medication adherence and therapy-
specific adherence. In the 6-month period following SafeMed index discharge, overall 
adherence decreased in both enrollees and controls. Although the magnitude of decline in 
adherence was greater among controls than enrollees, this difference was not statistically 
significant. DID estimate for overall adherence was +5 percentage points (DID: 0.05; 
Confidence Interval (CI), -0.28, 0.39). Similar patterns were observed for diabetes drug 
class where the DID estimate was +38 percentage points, but the results were not  
statistically significant (DID: 0.38; CI, -0.94, 1.69). For COPD/asthma medication class, 
following the SafeMed intervention, adherence increased in enrollees, whereas decreased
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Table 4-1. Baseline Characteristics of the Study Population 
 
 Before Matching  After Matching 
Characteristic Enrollees 
N=152 
Controls 
N=970 
P 
Value 
 Enrollees 
N=152 
Controls 
N=304 
P 
Value 
Age, mean (SD) 
Age>65  
52.2 (13.7) 
34 (22.5) 
59.7 (15.2) 
359 (37.1) 
<0.001 
<0.001 
 55.2 (13.7) 
39 (25.7) 
56.0 (15.2) 
87 (28.6) 
0.580 
0.505 
Female sex 97 (63.8) 585 (60.3) 0.410  97 (63.8) 186 (61.2) 0.585 
Race 
Non-Hispanic White 
Black 
Hispanic/Others 
 
16 (10.5) 
117 (77.0) 
19 (12.5) 
 
241 (24.9) 
666 (68.7) 
63 (6.5) 
 
<0.001 
  
16 (10.5) 
117 (77.0) 
19 (12.5) 
 
27 (8.9) 
242 (79.6) 
35 (11.5) 
 
0.793 
Insurance 
Medicare Only 
Medicaid Only 
Dual Eligible 
 
18 (11.8) 
79 (52.0) 
55 (36.2) 
 
217 (22.4) 
317 (32.7) 
436 (45.0) 
 
<0.001 
 
 
  
18 (11.8) 
79 (52.0) 
55 (36.2) 
 
41 (13.5) 
131 (43.1) 
132 (43.4) 
 
0.198 
Qualifying chronic conditions 
Diabetes 
Hypertension 
Congestive heart failure 
Coronary artery disease 
Asthma 
COPD 
Anxiety or Depression 
Charlson comorbidity index, 
mean (SD) 
 
108 (71.1) 
147 (96.7) 
104 (68.4) 
83 (54.6) 
64 (42.1) 
89 (58.6) 
39 (25.7) 
4.4 (2.2) 
 
594 (61.2) 
945 (97.4) 
606 (62.5) 
509 (52.5) 
286 (29.5) 
419 (43.2) 
312 (32.2) 
4.8 (2.7) 
 
0.020 
0.613 
0.157 
0.625 
0.002 
0.004 
0.108 
0.042 
  
108 (71.1) 
147 (96.7) 
104 (68.4) 
83 (54.6) 
64 (42.1) 
83 (54.6) 
39 (25.7) 
4.4 (2.2) 
 
209 (68.8) 
293 (96.4) 
213 (70.1) 
156 (51.3) 
111 (36.5) 
156 (51.3) 
85 (28.0) 
4.4 (2.3) 
 
0.615 
0.857 
0.719 
0.507 
0.247 
0.507 
0.602 
0.965 
Total amount paid by 
Medicare or TennCare, mean 
(SD) 
340.9 (509.7) 288.7 (522.3) 0.251  340.9 (509.7) 325.6 (617.8) 0.792 
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Figure 4-1. Average Proportion of Days Covered in the Pre- and Post-
Intervention Period 
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Table 4-2. Multivariate Difference-in-Differences Analysis Comparing Medication Adherence Between SafeMed 
Intervention Group and Control Group (by Therapy Class) 
 
 Pre-Intervention Period  Post-Intervention Period   
Drug Class SafeMed 
Group 
(T) 
Control 
Group 
(C) 
Difference 
(T-C) 
95% CI  SafeMed 
Group 
(T) 
Control 
Group 
(C) 
Difference 
(T-C) 
95% CI Difference 
in 
Differences 
95% CI 
All Drug Classes 0.58 0.80 -0.22 -0.50,0.05  0.36 0.53 -0.17 -0.36,0.02 0.05 -0.28,0.39 
Diabetes 0.98 1.63 -0.65 -0.71,0.42  0.75 1.02 -0.27 -1.04,0.51 0.38 -0.94,1.69 
CVD 0.73 0.81 -0.08 -0.40,0.23  0.50 0.63 -0.13 -0.36,0.11 -0.04 -0.40,0.32 
COPD/Asthma 0.36 0.94 -0.58 -1.10,-0.05  0.45 0.74 -0.29 -0.75,0.16 0.28 -0.40,0.96 
 
Significant at P < .05 
Adherence estimates are probability-scale predictions, adjusted for age, race, gender, insurance, Charlson comorbidity index, and 
anxiety or depression. 
CVD: Cardiovascular disease 
All drug classes: N=912 
Diabetes drug class (oral diabetes medications): N=192 
CVD drug class: N=870 
COPD/asthma drug class (long-term controller medications): N=270 
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in controls. However, this positive effect of the intervention was not statistically 
significant (DID: 0.28; CI, -0.40, 0.96).  
 
Table 4-3 shows the DID results among various sub-group populations. We found 
similar adherence trends across all sub-group populations. Following the SafeMed 
intervention, there was a decline in overall adherence in both enrollees and controls. For 
patients >65 years of age, Medicare only, and those with <4 comorbidities, there was a 
greater decline in overall adherence among controls, which is indicated by positive DID 
estimates. However, for patients <65 years of age, Medicaid only, dual eligibles, and 
those with >4 comorbidities, there was a greater decline in overall adherence among 
enrollees, which is indicated by negative DID estimates. None of the DID estimates were 
statistically significant. 
 
Figure 4-2 shows DID results for >1 diabetes medication fill among patients 
diagnosed with diabetes. Following intervention, the probability of filling >1 oral 
diabetes medications increased only among enrollees, which is indicated by a positive 
DID estimate (DID: 0.19; CI: -0.05, 0.42). Similarly, among patients diagnosed with 
COPD or asthma, the probability of using >1 long-term controller medication increased 
among enrollees—indicated by a positive DID estimate (DID: 0.38; CI: -0.30, 1.05) 
(Figure 4-3). However, among patients diagnosed with CHF, after intervention the 
probability of filling >1 COPD/asthma medications decreased among enrollees—
indicated by a negative DID estimate (DID: -0.86; CI: -1.93, 0.21) (Figure 4-4). 
 
 
DISCUSSION 
 
In this quasi-experimental study, we found that medication adherence was sub-
optimal among SafeMed enrollees and controls, and it decreased further from the pre-
intervention period to the post-intervention period. Combining the study findings from 
the analyses conducted on the 2-year baseline Medicare data (Chapter 2 and Chapter 3), 
this study shows a further decreasing trend in adherence over time among super-utilizers. 
Overall, the pharmacist-led medication management interventions as part of the SafeMed 
Program did not improve medication adherence in vulnerable super-utilizers with chronic 
conditions. However, for some sub-group populations, the intervention may have ensured 
that the decline in the probability of being adherent was not as low as it would have been 
in the absence of the intervention. Furthermore, although statistically insignificant, the 
SafeMed intervention had a positive impact on the use of COPD/asthma controller 
medications and oral diabetes medications. 
 
Considering the lack of statistical significance in the findings from this quasi-
experimental study, an important question that arises is why did this the intervention not 
bring about significant improvements in enrollees’ medication-related outcomes? As care 
transitions programs for super-utilizers are becoming more popular, it is important to 
understand whether medication management interventions as part of care transitions 
programs are successful in improving medication adherence among super-utilizers who 
are at a greater risk of experiencing drug therapy problems. The low rates of medication 
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Table 4-3. Multivariate Difference-in-Differences Analysis Comparing Medication Adherence Between SafeMed 
Intervention Group and Control Group (by Subgroups) 
 
 Pre-Intervention Period  Post-Intervention Period   
Measure SafeMed 
Group 
(T) 
Control 
Group 
(C) 
Difference 
(T-C) 
95% CI  SafeMed 
Group 
(T) 
Control 
Group 
(C) 
Difference 
(T-C) 
95% CI Difference 
in 
Differences 
95% CI 
Age<65 years 0.49 0.62 -0.13 -0.40,0.14  0.27 0.49 -0.22 -0.41,-0.03 -0.09 -0.42,0.24 
Age>65 years 0.91 1.52 -0.60 -1.64,0.43  0.68 0.64 0.04 -0.50,0.57 0.64 -0.50,1.78 
Medicare Only 0.64 1.41 -0.78 -1.8,0.30  0.50 0.46 0.04 -0.55,0.62 0.81 -0.34,1.96 
Medicaid Only 0.45 0.47 -0.01 -0.29,0.26  0.22 0.30 -0.07 -0.26,0.11 -0.06 -0.37,0.25 
Dual Eligible 0.66 0.95 -0.29 -0.79,0.22  0.51 0.83 -0.31 -0.73,0.10 -0.03 -0.62,0.57 
<4 Charlson 
Comorbidity Index 
0.38 0.65 -0.27 -0.62,0.08  0.19 0.30 -0.12 -0.32,0.09 0.16 -0.21,0.52 
>4 Charlson 
Comorbidity Index 
0.68 0.87 -0.19 -0.57,0.19  0.47 0.70 -0.23 -0.52,0.07 -0.04 -0.48,0.41 
 
Significant at P < .05 
Adherence estimates are probability-scale predictions, adjusted for age, race, gender, insurance, Charlson comorbidity index, and 
anxiety or depression. 
Sample for Age <65 years: N=660 
Sample for Age>65 years: N=252 
Sample for Medicare Only: N=118 
Sample for TennCare Only: N=420 
Sample for Dual Eligible: N=374 
Sample for <4 Charson comorbidity index: N=338 
Sample for >4 Charson comorbidity index: N=574 
 
 56 
 
 
Figure 4-2. Multivariate Difference-in-Differences Analysis for ≥1 Oral Diabetes 
Medication Fill in Patients Diagnosed with Diabetes (N=634) 
 
Note: Significant at P < .05. Adherence estimates are probability-scale predictions, 
adjusted for age, race, gender, insurance, Charlson comorbidity index, and anxiety or 
depression. 
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Figure 4-3. Multivariate Difference-in-Differences Analysis for ≥1 Long-Term 
Controller Medication Fill in Patients Diagnosed with COPD or Asthma (N=582) 
 
Note: Significant at P < .05. Adherence estimates are probability-scale predictions, 
adjusted for age, race, gender, insurance, Charlson comorbidity index, and anxiety or 
depression. 
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Figure 4-4. Multivariate Difference-in-Differences Analysis for ≥1 ACE/ARB Fill 
in Patients Diagnosed with CHF (N=634) 
 
Note: Significant at P < .05. Adherence estimates are probability-scale predictions, 
adjusted for age, race, gender, insurance, Charlson comorbidity index, and anxiety or 
depression. 
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adherence, even after intensive discharge preparation, planning, education, and care 
coordination services through the pharmacist-led medication management interventions, 
suggests that intensive investment in medication management interventions in this 
vulnerable population may not be sufficient. The study findings indicate that especially 
among patients <65 years of age, dual eligible beneficiaries, Medicaid beneficiaries, and 
those with multimorbidity, positive outcomes from interventions influencing patient 
behavior are difficult to achieve. Medication management interventions alone may not 
work for these high-risk patients and there may be other important barriers that need to be 
addressed to improve medication adherence in these high-risk sub-group populations. 
 
Drug costs are one such factor that may contribute to sub-optimal medication 
adherence in super-utilizers, specifically among Medicaid and dual eligibles. Choudhry 
and colleagues found that eliminating out-of-pocket costs improved medication 
adherence in patients discharged after myocardial infarction.101 In our prior work on 
super-utilizers, patients experiencing high rates of medication discrepancies reported one 
of the major contributors to post-discharge medication discrepancies being difficulty in 
paying for medications.13 Furthermore, in our previous study (Chapter 2), we found lower 
adherence for dual eligible beneficiaries receiving low-income subsidy. These are strong 
indications that current medication cost subsidy amounts may not be sufficient to achieve 
optimal adherence, and cost and affordability continue to remain significant barriers 
among this high-risk patient population. Additional barriers to post-discharge medication 
discrepancies reported by SafeMed enrollees in our previous study included 
transportation and unavailability of needed prescription drugs before discharge.13 Future 
interventions and their evaluations should explore alternative approaches to increasing 
access to essential medications, especially for Medicaid and dual eligible beneficiaries, 
such as providing bedside delivery, or providing essential medications at zero out-of-
pocket costs for patients. At policy-level, increasing days’ supply for essential chronic 
medications may help in improving adherence in this high-risk population. 
 
Results of studies evaluating the impact of pharmacist-led interventions during 
care transitions on medication-related outcomes have been mixed.17,19,49,54,98,102 
Consistent with our results, few studies examining the impact of care transitions 
programs on medication-related outcomes did not find any significant effect on 
medication-related outcomes. For instance, Kripalani and colleagues did not find any 
positive effect of pharmacist-led interventions on post discharge medication errors in 
patients with acute coronary syndromes or acute decompensated heart failure.19 
Additionally, in a sample of patients discharged to home and at high risk for medication-
related problems, Walker and colleagues found that although pharmacist interventions 
improved quality of patient’s discharge by identifying medication discrepancies, there 
was no effect on hospital readmissions and ED visits.54 A direct comparison with their 
findings is limited by the fact that our study focused explicitly on high-risk super-
utilizing patients residing in medically underserved areas. Moreover, our interventions 
were not only provided during hospital discharge but also extended beyond hospital 
discharge into the community. Ho and colleagues, who targeted patients from the 
Department of Veteran Affairs, found a positive impact of the post-discharge pharmacist-
led interventions on adherence measured over a period or 1 year.49 The different patient 
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populations and variations in program components and time frame for measuring 
adherence may account for differences in results. Our study findings suggest that super-
utilizers are a complex patient population to intervene and extending medication 
management services even to their homes may face significant challenges in improving 
their adherence to needed life-saving medications. 
 
Our results have important implications for health care systems striving to 
improve medication adherence and overall quality of care for vulnerable super-utilizers. 
Our analysis showed that adherence was suboptimal among super-utilizers and it declined 
over time. Furthermore, the study suggests that certain patient populations such as elderly 
Medicare beneficiaries and patients with lower comorbidities may be more amenable to 
medication management interventions. However, we found that despite providing 
intensive medication management interventions by a team of pharmacists and pharmacy 
technicians, there was no positive effect on medication adherence. This indicates that 
traditional medication management interventions during care transitions may not be 
enough for these patients and other alternative strategies such as addressing social risk 
factors and removing cost barriers may be needed to improve adherence in this 
population. Moreover, our work represents a real-world scenario where the SafeMed staff 
faced challenges in contacting and scheduling home visits and phone follow-ups with 
patients during the early implementation phase of the program. Initially we could not 
provide interventions to many patients. However, after extensive program improvement 
efforts, there was a significant improvement in the intervention completion rates.60 
Providing interventions to high-risk patient population is challenging and it is difficult to 
achieve full program potential as anticipated in a real-world setting. 
 
The negative effect of these medication management interventions on adherence 
could be partly due to limitations of this study. One of the major limitations of this study 
is the small sample size. Because of the incomplete Medicare Part D data on enrollees 
and controls who became eligible from July 1, 2014 to May 1, 2015, the study findings 
should be interpreted with caution. In future, we aim to reanalyze data for this study 
using complete data for our Medicare-eligible enrollees and controls. Additionally, a key 
question that arises is to what extent the negative findings are generalizable to other 
settings? Because this study specifically focused on publicly insured super-utilizers living 
in a medically underserved area with multimorbidity, it may only be generalizable to a 
similar setting and a similar population. And, the efficacy of this intervention may differ 
in less vulnerable populations. Furthermore, non-randomized studies may produce 
selection bias; however, this study used propensity score matching, which minimized the 
selection bias and unobserved confounding was minimized because of the quasi-
experimental study design. Additionally, the follow-up period for this study was 6 
months, which limits examination of long-term effects of the SafeMed program on 
medication adherence. Finally, the PDC measure for calculating adherence was an 
indirect method and may not accurately capture medication use and is likely to be biased 
for inhalation products that are prescribed for asthma and COPD. 
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CONCLUSION 
 
In conclusion, the rates of medication adherence among super-utilizers with 
chronic conditions were suboptimal, and adherence declined from the pre- to the post-
intervention period. Overall we found that medication management interventions as part 
of the SafeMed Program did not improve adherence in enrollees compared to controls. 
However, for patients diagnosed with COPD/asthma and diabetes, there were positive 
medication use trends in favor of enrollees. The study findings suggest that intensive 
medication management interventions provided beyond hospital discharge may not be 
enough to achieving optimal adherence in super-utilizers with chronic conditions, 
especially among Medicaid and dual eligible beneficiaries. Future studies are needed to 
test alternative strategies focused on increasing access to essential chronic medications in 
this vulnerable population. 
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CHAPTER 5.    CONCLUSION 
 
 
SUMMARY OF FINDINGS 
 
Our retrospective panel data analysis of the 2-year data showed that the 
proportion of patients who were nonadherent to their essential chronic disease 
medications ranged from 45.7% to 58.4%, with the highest rate for COPD/Asthma 
medications (54.3% to 64.4%). Nonadherence rates for cardiovascular and COPD/asthma 
medications were higher in the fourth period than previous periods. Additionally, of 
1,092 patients who met the super-utilizers criteria in the fourth period (qualifying period 
for the SafeMed Program), only about 14% of them were super-utilizers in all previous 
periods. The baseline characteristics demonstrated that majority of super-utilizers were 
female, non-Hispanic black, dual eligible beneficiaries, and received low-income cost 
sharing subsidy (LICS). Furthermore, the study subjects had high rates of mental illness, 
substance use disorder, and opioid medication use. During the final 6-month period, 57% 
of the study subjects were diagnosed with depression or anxiety or had filled 
antidepressants or anxiolytics, 32% were diagnosed with tobacco use disorder, and 69% 
had filled opioid medications. The multivariate analysis showed that all three major 
factors—the predisposing, enabling, and need factors were associated with medication 
nonadherence. The risk factors for medication nonadherence included age <65 years as a 
predisposing factor, dual beneficiaries receiving LICS and higher number of unique 
prescribers as enabling factors, and >4 opioid medications filled in the previous period as 
a need factor. Mental illness was not significantly associated with medication 
nonadherence in the multivariate analysis. Factors associated with lower odds of 
nonadherence included number of different medications filled as a need factor and >1 
physician office visits in the previous period as an enabling factor. 
 
When examining the associations between medication nonadherence, and 
inpatient and ED use, as part of the second aim of this dissertation, we found higher 
incidences of inpatient hospitalizations and ED visits among beneficiaries who were not 
adherent to their essential chronic medications. Specifically, we found that among elderly 
Medicare beneficiaries, nonadherence was significantly associated with a 57% increase in 
inpatient hospitalizations, and among non-elderly Medicare beneficiaries, nonadherence 
was significantly associated with 41% increase in inpatient stays and 25% increase in ED 
visits. Similar associations were found across all therapy classes examined (diabetes, 
cardiovascular, and COPD/asthma) in both age groups. However, nonadherence to 
diabetes and COPD/asthma drugs was not significantly associated with ED visits. 
Furthermore, we found that while the effects of nonadherence on inpatient stays were 
seen in both age groups, the effects of nonadherence on ED visits were more pronounced 
for younger Medicare patients. The study findings were consistent with prior research on 
Medicare population which showed nonadherence to be associated with higher incidence 
of hospitalizations.6,39 However, unlike previous studies based on Medicare population, 
this study focused specifically on super-utilizing Medicare patients with chronic 
conditions and polypharmacy. Moreover, our study population was disproportionately 
represented by dual beneficiaries <65 years of age, who had on average higher 
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comorbidities and were more likely to be nonadherent to their essential chronic 
medications than elderly patients. Given these differences, examining associations 
separately in the two age groups may help researchers to target these high utilizing 
patient populations better with medication management interventions. 
 
Based on Andersen behavioral model of health services utilization, we found that 
all three major categories—predisposing, enabling, and need factors were associated with 
higher inpatient and ED utilization. Among need factors, mental illness was a risk factor 
for higher utilization among elderly and substance use disorder was a risk factor for 
higher inpatient utilization among non-elderly Medicare patients. Additionally, the 
predisposing risk factor included non-Hispanic black race and the enabling risk factor 
included dual LICS status. 
 
Finally, as part of the third aim, this study examined the impact of the SafeMed 
Program on medication utilization and adherence among study participants compared 
with propensity-matched controls. The study found that the proportion of adherent 
patients (PDC >80%) among enrollees declined from 34.2% in the pre-intervention 
period to 25.0% in the post-intervention period, while among controls, this proportion 
declined from 41.1% to 32.6%. Thus, medication adherence was suboptimal among 
SafeMed enrollees and controls, and it decreased further from the pre-intervention period 
to the post-intervention period. Combining the study findings from the analyses 
conducted on the 2-year baseline Medicare data (Chapter 2 and Chapter 3), this study 
shows a further decreasing trend in adherence over time among super-utilizers. The 
multivariate analyses demonstrated that the pharmacist-led medication management 
interventions as part of the SafeMed Program did not improve medication adherence in 
vulnerable super-utilizers with chronic conditions. However, for some sub-group 
populations including Medicare only beneficiaries, patients >65 years of age, and patients 
with a lower number of comorbidities, the intervention may have ensured that the decline 
in the probability of being adherent was not as low as it would have been in the absence 
of the intervention. Furthermore, although statistically insignificant, the SafeMed 
intervention had a positive impact on the use of COPD/asthma controller medications and 
oral diabetes medications. 
 
 
IMPLICATIONS FOR PRACTICE AND POLICY 
 
This study has important implications for policy makers and institutions striving 
to improve the quality of care and reducing health care utilization and costs for super-
utilizers with chronic conditions. The literature on super-utilizers is sparse and mainly 
focuses on describing the population and their hospitalization patterns.56,57 This study is 
the first to our knowledge to demonstrate the magnitude and importance of medication 
nonadherence in vulnerable super-utilizers with chronic conditions. We not only found 
high rates of nonadherence among super-utilizers but also saw an increase in the 
nonadherence rates when patients had more frequent hospitalizations and ED visits. The 
study findings suggest that medication nonadherence is a significant problem among 
super-utilizers, and greater efforts may be needed to address this issue. 
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The predisposing, enabling, and need-related risk factors for nonadherence 
identified in this study may enable hospitals, accountable care organizations and managed 
care organizations identify super-utilizing populations in need of medication management 
interventions. Managing medication-related adverse events and improving medication 
adherence among vulnerable super-utilizers is critical for hospitals and payers since 75% 
of the hospital readmissions among Medicare population are considered potentially 
preventable, resulting in $12 billion in unnecessary Medicare spending each year and 
subjecting hospitals to readmission penalties.46 The study suggests that non-elderly 
Medicare patients, dual beneficiaries receiving low-income subsidy, and patients using a 
higher number of opioid medications are at greater risk for nonadherence. These high-
risk patient populations may merit targeted interventions to support essential chronic 
disease medication adherence. Despite receiving low-income subsidy, dual beneficiaries 
were less likely to adhere to their therapy. This indicates that for super-utilizing low-
income dual beneficiaries, subsidies may not be sufficient to achieve optimal adherence, 
and cost remains a significant barrier to achieving optimal adherence. Additionally, 
highly statistically significant and large effect size of the association between age and 
medication nonadherence demonstrates the need for better targeting of the non-elderly 
Medicare group with medication management interventions. The study findings suggest 
the importance of making routine visits to providers who can play a significant role in 
helping patients to adhere to their essential chronic medications. And, it also highlights 
the importance of reducing prescribing complexity in this high-risk patient population, 
which may result in suboptimal adherence. 
 
Our study findings further demonstrate that improving medication adherence—a 
patient behavioral factor very amenable to change—may be critical in reducing inpatient 
and ED use among Medicare super-utilizers with chronic conditions. In our previous 
study, we found that during care transitions processes from the hospital to the community 
setting, super-utilizers were at high risk for drug therapy problems and medication 
discrepancies, which may result in suboptimal adherence.13 This cyclical process of 
nonadherence leading to increased frequency of hospitalizations, causing drug therapy 
problems and medication discrepancies in super-utilizers, can have detrimental effects on 
their health outcomes. Given these findings, hospitals, managed care organizations, and 
payers should engage in programs aimed at resolving drug therapy problems and 
improving medication adherence in super-utilizing populations. By examining 
associations for inpatient and ED use separately among non-elderly and elderly Medicare 
beneficiaries, this study indicates that there are variations in effects within these groups. 
For instance, mental illness was a risk factor for higher inpatient and ED utilization 
among elderly, while substance use disorder was a risk factor for higher inpatient 
utilization among younger patients. The study findings suggest that the two patient 
groups may have different barriers and varying social and medical needs, which are 
essential to be taken into consideration when designing interventions for these vulnerable 
patients. Additionally, our findings highlight the vulnerability of non-Hispanic blacks and 
low-income dual eligible beneficiaries who are at a higher risk for inpatient and ED 
utilization. Policy makers need to pay greater attention to the needs of these patient 
populations. 
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Our study findings have important implications for health care systems striving to 
improve medication adherence and overall quality of care for vulnerable super-utilizers. 
The study found that despite providing intensive medication management interventions 
by a team of pharmacists and pharmacy technicians, there was no positive effect on 
medication adherence. However, for some sub-group populations (Medicare only, elderly 
Medicare patients, and patients with lower comorbidity), the intervention may have 
ensured that the decline in the probability of being adherent was not as low as it would 
have been in the absence of the intervention. Furthermore, although statistically 
insignificant, the SafeMed intervention had a positive impact on the use of COPD/asthma 
controller medications and oral diabetes medications. These findings indicate that 
traditional medication management interventions during care transitions may not be 
sufficient for these high-risk patients and other alternative strategies such as addressing 
social risk factors, and removing cost barriers may be needed to improve adherence, 
especially among low-income dual beneficiaries, Medicaid enrollees, and patients with 
higher comorbidity. 
 
Finally, our findings showing a high prevalence of mental illness, substance use 
disorder, and opioid medication use have highlighted the importance of monitoring for 
signs of opioid abuse, and having a strong social support and mental health facilities for 
vulnerable super-utilizing populations who have complex medical and social needs. 
Patients with complex behavioral health issues could benefit from greater coordination of 
health care providers and health care systems and having access to high-quality mental 
health services.  
 
 
IMPLICATIONS FOR FUTURE RESEARCH 
 
We found that the pharmacist-led medication management interventions as part of 
the SafeMed Program did not improve medication adherence in vulnerable super-utilizers 
with chronic conditions. Drug costs are one such factor that may contribute to suboptimal 
medication adherence in super-utilizers, specifically among low-income Medicaid and 
dual eligible beneficiaries. In our previous study (Chapter 2, Chapter 3), we found lower 
adherence and higher inpatient and ED utilization for dual eligible beneficiaries receiving 
low-income subsidies. These are strong indications that current medication cost subsidy 
amounts may not be sufficient to achieve optimal adherence and reduce utilization, and 
cost and affordability continue to remain significant barriers among this high-risk patient 
population. Additional barriers to post-discharge medication discrepancies reported by 
SafeMed enrollees in our previous study included transportation and unavailability of 
needed prescription drugs before discharge.13 Future interventions and their evaluations 
should explore alternative approaches to increasing access to essential medications, 
especially for low-income Medicaid and dual eligible beneficiaries, such as using hospital 
outpatient pharmacies to fill medications, providing bedside delivery, providing essential 
medications at zero out-of-pocket costs for patients, or increasing days’ supply for 
essential chronic disease medications. 
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We used Medicare claims data to examine the factors associated with medication 
nonadherence (Aim 1) and the association between nonadherence and health care 
utilization (Aim 2). The follow-up of this study would analyze these aims using 
TennCare claims data to provide a comprehensive picture of the predictors of 
nonadherence and the association between nonadherence and health care utilization in the 
vulnerable TennCare population. Additionally, one of the major limitations of the study 
examining the impact of the SafeMed Program on medication use and adherence was 
small sample size. Because of the incomplete Medicare Part D data on enrollees and 
controls who became eligible from July 1, 2014 to May 1, 2015, the study findings 
should be interpreted with caution. In future, we aim to reanalyze data for this study 
using complete data for Medicare-eligible enrollees and controls. Finally, costs associated 
with medication nonadherence among super-utilizers are an important outcome and may 
be of more interest to policymakers. The follow-up to this study would examine the costs, 
including total costs and costs specific to health care services from the payer perspective.  
 
 
  
 67 
LIST OF REFERENCES 
 
 
1. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in 
cardiovascular outcomes. Circulation. Jun 16 2009;119(23):3028-3035. 
 
2. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in 
pharmacy administrative databases: a proposal for standard definitions and 
preferred measures. The Annals of pharmacotherapy. Jul-Aug 2006;40(7-8):1280-
1288. 
 
3. Bailey JE, Hajjar M, Shoib B, Tang J, Ray MM, Wan JY. Risk factors associated 
with antihypertensive medication nonadherence in a statewide Medicaid 
population. The American journal of the medical sciences. Nov 2014;348(5):410-
415. 
 
4. Jha AK, Aubert RE, Yao J, Teagarden JR, Epstein RS. Greater adherence to 
diabetes drugs is linked to less hospital use and could save nearly $5 billion 
annually. Health affairs. Aug 2012;31(8):1836-1846. 
 
5. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication 
adherence leads to lower health care use and costs despite increased drug 
spending. Health affairs. Jan 2011;30(1):91-99. 
 
6. Simoni-Wastila L, Wei YJ, Qian J, et al. Association of chronic obstructive 
pulmonary disease maintenance medication adherence with all-cause 
hospitalization and spending in a Medicare population. The American journal of 
geriatric pharmacotherapy. Jun 2012;10(3):201-210. 
 
7. Osterberg L, Blaschke T. Adherence to medication. The New England journal of 
medicine. Aug 4 2005;353(5):487-497. 
 
8. PQA Measures Used By CMS in the Star Ratings. Pharmacy Quality Alliance 
Website. http://pqaalliance.org/measures/cms.asp. Accessed October 1, 2016. 
 
9. Coleman EA. Falling through the cracks: challenges and opportunities for 
improving transitional care for persons with continuous complex care needs. 
Journal of the American Geriatrics Society. Apr 2003;51(4):549-555. 
 
10. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. The incidence and 
severity of adverse events affecting patients after discharge from the hospital. 
Annals of internal medicine. Feb 4 2003;138(3):161-167. 
 
11. Fischer MA, Choudhry NK, Brill G, et al. Trouble getting started: predictors of 
primary medication nonadherence. The American journal of medicine. Nov 
2011;124(11):1081 e1089-1022. 
 68 
12. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clinic 
proceedings. Apr 2011;86(4):304-314. 
 
13. Surbhi S, Munshi KD, Bell PC, Bailey JE. Drug therapy problems and medication 
discrepancies during care transitions in super-utilizers. Journal of the American 
Pharmacists Association : JAPhA. Oct 6 2016. 
 
14. Kripalani S, Henderson LE, Jacobson TA, Vaccarino V. Medication use among 
inner-city patients after hospital discharge: patient-reported barriers and solutions. 
Mayo Clinic proceedings. May 2008;83(5):529-535. 
 
15. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-
based secondary prevention therapies in coronary artery disease. Circulation. Jan 
17 2006;113(2):203-212. 
 
16. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy 
discontinuation on mortality after myocardial infarction. Archives of internal 
medicine. Sep 25 2006;166(17):1842-1847. 
 
17. Schnipper JL, Kirwin JL, Cotugno MC, et al. Role of pharmacist counseling in 
preventing adverse drug events after hospitalization. Archives of internal 
medicine. Mar 13 2006;166(5):565-571. 
 
18. Coleman EA, Smith JD, Raha D, Min SJ. Posthospital medication discrepancies: 
prevalence and contributing factors. Archives of internal medicine. Sep 12 
2005;165(16):1842-1847. 
 
19. Kripalani S, Roumie CL, Dalal AK, et al. Effect of a pharmacist intervention on 
clinically important medication errors after hospital discharge: a randomized trial. 
Annals of internal medicine. Jul 3 2012;157(1):1-10. 
 
20. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. Adverse drug events 
occurring following hospital discharge. Journal of general internal medicine. Apr 
2005;20(4):317-323. 
 
21. Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to 
multiple related medications. The American journal of managed care. Jul 
2009;15(7):457-464. 
 
22. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a 
medication adherence measure in an outpatient setting. Journal of clinical 
hypertension. May 2008;10(5):348-354. 
 
23. Kripalani S, Risser J, Gatti ME, Jacobson TA. Development and evaluation of the 
Adherence to Refills and Medications Scale (ARMS) among low-literacy patients 
 69 
with chronic disease. Value in health : the journal of the International Society for 
Pharmacoeconomics and Outcomes Research. Jan-Feb 2009;12(1):118-123. 
 
24. Gehi A, Haas D, Pipkin S, Whooley MA. Depression and medication adherence 
in outpatients with coronary heart disease: findings from the Heart and Soul 
Study. Archives of internal medicine. Nov 28 2005;165(21):2508-2513. 
 
25. Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG. Impact of a prescription 
copayment increase on lipid-lowering medication adherence in veterans. 
Circulation. Jan 27 2009;119(3):390-397. 
 
26. Charles H, Good CB, Hanusa BH, Chang CC, Whittle J. Racial differences in 
adherence to cardiac medications. Journal of the National Medical Association. 
Jan 2003;95(1):17-27. 
 
27. Taira DA, Wong KS, Frech-Tamas F, Chung RS. Copayment level and 
compliance with antihypertensive medication: analysis and policy implications for 
managed care. The American journal of managed care. Nov 2006;12(11):678-
683. 
 
28. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare 
drug benefits. The New England journal of medicine. Jun 1 2006;354(22):2349-
2359. 
 
29. Gazmararian JA, Kripalani S, Miller MJ, Echt KV, Ren J, Rask K. Factors 
associated with medication refill adherence in cardiovascular-related diseases: a 
focus on health literacy. Journal of general internal medicine. Dec 
2006;21(12):1215-1221. 
 
30. Davis TC, Wolf MS, Bass PF, 3rd, et al. Literacy and misunderstanding 
prescription drug labels. Annals of internal medicine. Dec 19 2006;145(12):887-
894. 
 
31. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. 
The New England journal of medicine. Apr 17 2003;348(16):1556-1564. 
 
32. Coleman EA, Mahoney E, Parry C. Assessing the quality of preparation for 
posthospital care from the patient's perspective: the care transitions measure. 
Medical care. Mar 2005;43(3):246-255. 
 
33. Calkins DR, Davis RB, Reiley P, et al. Patient-physician communication at 
hospital discharge and patients' understanding of the postdischarge treatment plan. 
Archives of internal medicine. May 12 1997;157(9):1026-1030. 
 
34. Kripalani S, LeFevre F, Phillips CO, Williams MV, Basaviah P, Baker DW. 
Deficits in communication and information transfer between hospital-based and 
 70 
primary care physicians: implications for patient safety and continuity of care. 
Jama. Feb 28 2007;297(8):831-841. 
 
35. Makaryus AN, Friedman EA. Patients' understanding of their treatment plans and 
diagnosis at discharge. Mayo Clinic proceedings. Aug 2005;80(8):991-994. 
 
36. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on 
hospitalization and mortality among patients with diabetes mellitus. Archives of 
internal medicine. Sep 25 2006;166(17):1836-1841. 
 
37. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated 
with a broad range of adverse outcomes in patients with coronary artery disease. 
American heart journal. Apr 2008;155(4):772-779. 
 
38. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication 
adherence on hospitalization risk and healthcare cost. Medical care. Jun 
2005;43(6):521-530. 
 
39. Zhang Y, Kaplan CM, Baik SH, Chang CC, Lave JR. Medication adherence and 
readmission after myocardial infarction in the Medicare population. The American 
journal of managed care. 2014;20(11):e498-505. 
 
40. Bunting BA, Smith BH, Sutherland SE. The Asheville Project: clinical and 
economic outcomes of a community-based long-term medication therapy 
management program for hypertension and dyslipidemia. Journal of the American 
Pharmacists Association : JAPhA. Jan-Feb 2008;48(1):23-31. 
 
41. Bunting BA, Cranor CW. The Asheville Project: long-term clinical, humanistic, 
and economic outcomes of a community-based medication therapy management 
program for asthma. Journal of the American Pharmacists Association : JAPhA. 
Mar-Apr 2006;46(2):133-147. 
 
42. Cranor CW, Bunting BA, Christensen DB. The asheville project: long-term 
clinical and economic outcomes of a community pharmacy diabetes care program. 
Journal of the American Pharmacists Association : JAPhA. Mar 2003;43(2):173-
184. 
 
43. Pringle JL, Boyer A, Conklin MH, McCullough JW, Aldridge A. The 
Pennsylvania Project: pharmacist intervention improved medication adherence 
and reduced health care costs. Health affairs. Aug 2014;33(8):1444-1452. 
 
44. Zillich AJ, Jaynes HA, Snyder ME, et al. Evaluation of specialized medication 
packaging combined with medication therapy management: adherence, outcomes, 
and costs among Medicaid patients. Medical care. Jun 2012;50(6):485-493. 
 
 71 
45. Martin MY, Kim YI, Kratt P, et al. Medication adherence among rural, low-
income hypertensive adults: a randomized trial of a multimedia community-based 
intervention. American journal of health promotion : AJHP. Jul-Aug 
2011;25(6):372-378. 
 
46. Improving Care Transitions. Better coordination of patient transfers among care 
sites and the community could save money and improve the quality of care. 
Health Policy Brief. Health Affairs. September 13, 2012. 
http://healthaffairs.org/healthpolicybriefs/brief_pdfs/healthpolicybrief_76.pdf. 
Accessed October 1, 2016. 
 
47. Kalista T, Lemay V, Cohen L. Postdischarge community pharmacist-provided 
home services for patients after hospitalization for heart failure. Journal of the 
American Pharmacists Association : JAPhA. Jul-Aug 2015;55(4):438-442. 
 
48. Kilcup M, Schultz D, Carlson J, Wilson B. Postdischarge pharmacist medication 
reconciliation: impact on readmission rates and financial savings. Journal of the 
American Pharmacists Association : JAPhA. Jan-Feb 2013;53(1):78-84. 
 
49. Ho PM, Lambert-Kerzner A, Carey EP, et al. Multifaceted intervention to 
improve medication adherence and secondary prevention measures after acute 
coronary syndrome hospital discharge: a randomized clinical trial. JAMA internal 
medicine. Feb 1 2014;174(2):186-193. 
 
50. Dudas V, Bookwalter T, Kerr KM, Pantilat SZ. The impact of follow-up 
telephone calls to patients after hospitalization. The American journal of 
medicine. Dec 21 2001;111(9B):26S-30S. 
 
51. Phatak A, Prusi R, Ward B, et al. Impact of pharmacist involvement in the 
transitional care of high-risk patients through medication reconciliation, 
medication education, and postdischarge call-backs (IPITCH Study). Journal of 
hospital medicine. Jan 2016;11(1):39-44. 
 
52. Boockvar KS, Carlson LaCorte H, Giambanco V, Fridman B, Siu A. Medication 
reconciliation for reducing drug-discrepancy adverse events. The American 
journal of geriatric pharmacotherapy. Sep 2006;4(3):236-243. 
 
53. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and 
inpatient medical care: a systematic review. Archives of internal medicine. May 8 
2006;166(9):955-964. 
 
54. Walker PC, Bernstein SJ, Jones JN, et al. Impact of a pharmacist-facilitated 
hospital discharge program: a quasi-experimental study. Archives of internal 
medicine. Nov 23 2009;169(21):2003-2010. 
 
 72 
55. Better care for super-utilizers. Robert Wood Johnson Foundation. 
http://www.rwjf.org/en/library/collections/super-utilizers.html. Accessed October 
1, 2016. 
 
56. Johnson TL, Rinehart DJ, Durfee J, et al. For many patients who use large 
amounts of health care services, the need is intense yet temporary. Health affairs. 
Aug 2015;34(8):1312-1319. 
 
57. Harris LJ, Graetz I, Podila PS, Wan J, Waters TM, Bailey JE. Characteristics of 
Hospital and Emergency Care Super-utilizers with Multiple Chronic Conditions. 
The Journal of emergency medicine. Apr 2016;50(4):e203-214. 
 
58. Jiang HJ, Weiss AJ, Barrett ML, Sheng M. Characteristics of Hospital Stays for 
Super-Utilizers by Payer, 2012: Statistical Brief #190. Healthcare Cost and 
Utilization Project (HCUP) Statistical Briefs. Rockville (MD)2015. 
 
59. Regenstein M, Andres E. Reducing hospital readmissions among medicaid 
patients: a review of the literature. Quality management in health care. Oct-Dec 
2014;23(4):203-225. 
 
60. Bailey JE, Surbhi S, Bell PC, Jones AM, Rashed S, Ugwueke MO. SafeMed: 
Using pharmacy technicians in a novel role as community health workers to 
improve transitions of care. Journal of the American Pharmacists Association : 
JAPhA. Jan 2016;56(1):73-81. 
 
61. Williams MV, Li J, Hansen LO, et al. Project BOOST implementation: lessons 
learned. Southern medical journal. Jul 2014;107(7):455-465. 
 
62. Integrating Care Across Settings: The Illinois Transitional Care Consortium’s 
Bridge Model. American Society on Aging Website. 
http://www.asaging.org/blog/integrating-care-across-settings-illinois-transitional-
care-consortium%E2%80%99s-bridge-model. Accessed October 1, 2016. 
 
63. Gans D, Hadler MW, Chen X, et al. Cost Analysis and Policy Implications of a 
Pediatric Palliative Care Program. Journal of pain and symptom management. Sep 
2016;52(3):329-335. 
 
64. Kaufman S, Ali N, DeFiglio V, Craig K, Brenner J. Early efforts to target and 
enroll high-risk diabetic patients into urban community-based programs. Health 
promotion practice. Nov 2014;15(2 Suppl):62S-70S. 
 
65. Coleman EA, Parry C, Chalmers S, Min SJ. The care transitions intervention: 
results of a randomized controlled trial. Archives of internal medicine. Sep 25 
2006;166(17):1822-1828. 
 
 73 
66. Naylor MD, Brooten DA, Campbell RL, Maislin G, McCauley KM, Schwartz JS. 
Transitional care of older adults hospitalized with heart failure: a randomized, 
controlled trial. Journal of the American Geriatrics Society. May 2004;52(5):675-
684. 
 
67. Andersen RM. Revisiting the behavioral model and access to medical care: does it 
matter? Journal of health and social behavior. Mar 1995;36(1):1-10. 
 
68. Murray MD, Morrow DG, Weiner M, et al. A conceptual framework to study 
medication adherence in older adults. The American journal of geriatric 
pharmacotherapy. Mar 2004;2(1):36-43. 
 
69. De Smet BD, Erickson SR, Kirking DM. Self-reported adherence in patients with 
asthma. The Annals of pharmacotherapy. Mar 2006;40(3):414-420. 
 
70. Riley GF. Long-term trends in the concentration of Medicare spending. Health 
affairs. May-Jun 2007;26(3):808-816. 
 
71. Gawande AA. The hot spotters: canwe lower medical costs by giving theneediest 
patients better care? New Yorker. 2011 Jan 4. 
 
72. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between 
dose regimens and medication compliance. Clinical therapeutics. Aug 
2001;23(8):1296-1310. 
 
73. Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic 
complexity on adherence to cardiovascular medications. Archives of internal 
medicine. May 9 2011;171(9):814-822. 
 
74. Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in 
Prescription and Over-the-Counter Medication and Dietary Supplement Use 
Among Older Adults in the United States, 2005 vs 2011. JAMA internal medicine. 
Apr 1 2016;176(4):473-482. 
 
75. Super-Utilizer Summit Common Themes from Innovative Complex Care 
Management Programs. 2013. http://www.chcs.org/media/FINAL_Super-
Utilizer_Report.pdf. Accessed October 1, 2016. 
 
76. Bailey JE, Binkley B. Using SafeMed model for transitions of care approach. 
Increasing engagement and adherence for complex patients. 
https://www.stepsforward.org/Static/images/modules/34/downloadable/Using_Saf
eMed_Model_for_Transitions_of_Care_Approach.pdf. Accessed October 1, 
2016. 
 
 74 
77. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the 
Medicare fee-for-service program. The New England journal of medicine. Apr 2 
2009;360(14):1418-1428. 
 
78. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the 
management of high blood pressure in adults: report from the panel members 
appointed to the Eighth Joint National Committee (JNC 8). Jama. Feb 5 
2014;311(5):507-520. 
 
79. Frequently Asked Questions about PQA Measure Development and Measures. 
http://pqaalliance.org/measures/faqs.asp. Accessed October 1, 2016. 
 
80. Concept: Charlson Comorbidity Index. Pharmacy Quality Alliance Website. 
Manitoba Centre for Health Policy. University of Manitoba Website. http://mchp-
appserv.cpe.umanitoba.ca/viewConcept.php?conceptID=1098. Accessed April, 
30, 2016. 
 
81. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly 
patients with and without acute coronary syndromes. Jama. Jul 24-31 
2002;288(4):462-467. 
 
82. Cramer JA. A systematic review of adherence with medications for diabetes. 
Diabetes care. May 2004;27(5):1218-1224. 
 
83. Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in 
patients treated for COPD. International journal of chronic obstructive pulmonary 
disease. 2008;3(3):371-384. 
 
84. Rieckmann N, Gerin W, Kronish IM, et al. Course of depressive symptoms and 
medication adherence after acute coronary syndromes: an electronic medication 
monitoring study. Journal of the American College of Cardiology. Dec 5 
2006;48(11):2218-2222. 
 
85. Bane C, Hughes CM, McElnay JC. The impact of depressive symptoms and 
psychosocial factors on medication adherence in cardiovascular disease. Patient 
education and counseling. Feb 2006;60(2):187-193. 
 
86. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for 
noncompliance with medical treatment: meta-analysis of the effects of anxiety 
and depression on patient adherence. Archives of internal medicine. Jul 24 
2000;160(14):2101-2107. 
 
87. Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient 
adherence. Therapeutics and clinical risk management. Sep 2005;1(3):189-199. 
 
 75 
88. Yala SM, Duru OK, Ettner SL, Turk N, Mangione CM, Brown AF. Patterns of 
prescription drug expenditures and medication adherence among medicare part D 
beneficiaries with and without the low-income supplement. BMC health services 
research. 2014;14:665. 
 
89. Stuart B, Yin X, Davidoff A, et al. Impact of Part D low-income subsidies on 
medication patterns for Medicare beneficiaries with diabetes. Medical care. Nov 
2012;50(11):913-919. 
 
90. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with 
antihypertensive and lipid-lowering therapy. Archives of internal medicine. May 
23 2005;165(10):1147-1152. 
 
91. Naylor MD, Sochalski JA. Scaling up: bringing the transitional care model into 
the mainstream. Issue brief. Nov 2010;103:1-12. 
 
92. Jena AB, Goldman D, Karaca-Mandic P. Hospital Prescribing of Opioids to 
Medicare Beneficiaries. JAMA internal medicine. Jul 1 2016;176(7):990-997. 
 
93. Torres-Reyna O. Panel Data Analysis Fixed and Random Effects using Stata (v. 
4.2). December, 2007. https://www.princeton.edu/~otorres/Panel101.pdf. 
Accessed October 1, 2016. 
 
94. Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in 
observational studies of preventive interventions: a primer for physicians. Journal 
of general internal medicine. May 2011;26(5):546-550. 
 
95. Rathore SS, Foody JM, Wang Y, et al. Race, quality of care, and outcomes of 
elderly patients hospitalized with heart failure. Jama. May 21 2003;289(19):2517-
2524. 
 
96. Joynt KE, Orav EJ, Jha AK. Thirty-day readmission rates for Medicare 
beneficiaries by race and site of care. Jama. Feb 16 2011;305(7):675-681. 
 
97. Kripalani S, Jackson AT, Schnipper JL, Coleman EA. Promoting effective 
transitions of care at hospital discharge: a review of key issues for hospitalists. 
Journal of hospital medicine. Sep 2007;2(5):314-323. 
 
98. Gil M, Mikaitis DK, Shier G, Johnson TJ, Sims S. Impact of a combined 
pharmacist and social worker program to reduce hospital readmissions. Journal of 
managed care pharmacy : JMCP. Sep 2013;19(7):558-563. 
 
99. Polinski JM, Moore JM, Kyrychenko P, et al. An Insurer's Care Transition 
Program Emphasizes Medication Reconciliation, Reduces Readmissions And 
Costs. Health affairs. Jul 1 2016;35(7):1222-1229. 
 
 76 
100. Parsons LS. Performing a 1:N Case-Control Match on Propensity Score. 
http://www2.sas.com/proceedings/sugi29/165-29.pdf. Accessed September 12, 
2016. 
 
101. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications 
after myocardial infarction. The New England journal of medicine. Dec 1 
2011;365(22):2088-2097. 
 
102. Kirkham HS, Clark BL, Paynter J, Lewis GH, Duncan I. The effect of a 
collaborative pharmacist-hospital care transition program on the likelihood of 30-
day readmission. American journal of health-system pharmacy : AJHP : official 
journal of the American Society of Health-System Pharmacists. May 1 
2014;71(9):739-745. 
 
 
  
 77 
APPENDIX A. SUPPLEMENTAL MATERIALS FOR CHAPTER 2 
 
 
Table A-1. The International Classification of Diseases, Ninth Revision, Clinical 
Modification [ICD-9-CM] Codes (Inclusion Criteria and Comorbidities) 
 
Categories ICD-9-CM Codes 
Qualifying Chronic 
Conditions 
 
Hypertension '36211','4010','4011','4019','40200','40201','40210','40211','40290','40291', 
'40300','40301','40310','40311','40390','40391','40400','40401','40402','40403', 
'40410','40411','40412','40413','40490','40491','40492','40493','40501','40509', 
'40511', '40519','40591','40599','4372' 
  
Congestive heart 
failure 
'39891','40201','40211','40291','40401','40403','40411','40413','40491','40493', 
'4254','4255','4257','4258','4259','4280','4281','42820','42821','42822','42823', 
'42830','42831','42832','42833','42840','42841','42842','42843','4289' 
  
Coronary artery 
disease  
'41000', '41001', '41002', '41010', '41011','41012', '41020', '41021', '41022', 
'41030', '41031', '41032', '41040', '41041', '41042', '41050','41051', '41052', 
'41060', '41061', '41062', '41070','41071', '41072', '41080', '41081', '41082', 
'41090', '41091', '41092', '4110', '4111', '41181', '41189', '412', '4130', '4131', 
'4139', '41400', '41401', '41402','41403','41404','41405','41406','41407','41412', 
'4142','4143','4148','4149','42979' 
  
Diabetes mellitus '24900','24901','24910','24911','24920','24921','24930','24931','24940','24941', 
'24950','24951','24960','24961','24970','24971','24980','24981','24990','24991', 
'25000','25001','25002','25003','25010','25011','25011','25012','25013','25020', 
'2502','25022','25023','25030','25031','25032','25033','25040','25041','25042', 
'25043','25050','25051','25052','25053','25060','25061','25062','25063','25070', 
'25071','25072','25073','25080','25081','25082','25083','25090','25091','25092', 
'25093','3572','36201','36202','36641' 
  
Asthma '49300','49301','49302','49310','49311','49312','49320','49321','49322','49381', 
'49382','49390','49391','49392' 
  
Chronic obstructive 
pulmonary disease  
'490','4910','4911','49120','49121','49122','4918','4919','4920','4928','4940','4941,
'496' 
  
Comorbidities  
Anxiety or 
depression 
'29384','30000','30001','30002','30009','30010','30020','30021','30022','30023', 
'30029','3003','3005','30089','3009','3080','3081','3082','3083','3084','3089','3091,
'3130','3131','31321','31322','3133','31382','31383','29383','29620','29621','2962',
'29623','29624','29625','29626','29630','29631','29632','29633','29634','29635', 
'29636','3004','311' 
  
Tobacco use disorder '3051' 
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Table A-2. Medication Nonadherence to Essential Chronic Disease Medication by 
Therapy Class 
 
Therapy Class Percent Nonadherent  
(PDC <80%) 
1. Diabetes medications 
Period 1 (n=250) 
Period 2 (n=269) 
Period 3 (n=298) 
Period 4 (n=300) 
Overall (n=1,117 patient-periods) 
 
41.2% 
48.7% 
58.4% 
67.3% 
53.3% 
2. Cardiovascular medications 
Period 1 (n=933) 
Period 2 (n=987) 
Period 3 (n=1,010) 
Period 4 (n=1,045) 
Overall (n=3,955 patient-periods) 
 
40.2% 
53.1% 
60.8% 
66.0% 
54.2% 
3. COPD/Asthma medications 
Period 1 (n=169) 
Period 2 (n=191) 
Period 3 (n=216) 
Period 4 (n=258) 
Overall (n=834 patient-periods) 
 
54.4% 
63.4% 
66.7% 
74.8% 
64.4% 
Diabetes, cardiovascular, and 
COPD/Asthma meds combined 
Period 1 (n=961) 
Period 2 (n=1,011) 
Period 3 (n=1,031) 
Period 4 (n=1,060) 
Overall (n=4,043 patient-periods) 
 
 
43.2% 
56.1% 
65.5% 
72.8% 
58.4% 
 
COPD: chronic obstructive pulmonary disease. 
COPD/Asthma medications included controller medications (anticholinergic inhalers, 
inhaled corticosteroids alone or in combination with long-acting beta-agonists (LABA), 
and other COPD/asthma medications (theophylline and leukotriene modifiers).
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Table A-3. Multivariate Associations with Medication Nonadherence Using 
Alternative Proportion of Days Covered (PDC) Definition (N=2,999 Patient-Periods) 
 
 Nonadherence 
Characteristics Odds Ratio (95% CI) P Value 
<65 years 2.14 (1.47-3.11) <0.001 
Female 1.32 (0.94-1.85) 0.114 
Non-Hispanic Black 1.03 (0.71-1.51) 0.863 
Non-dual LIS 
Dual LIS 
1.59 (0.88-2.86) 
1.62 (1.07-2.44) 
0.121 
0.021 
Comorbidity 
Charlson comorbidity index  
Diagnosis of tobacco abuse disorder  
Mental illness* 
 
1.14 (1.07-1.20) 
1.03 (0.70-1.52) 
1.00 (0.71-1.41) 
 
<0.001 
0.867 
0.987 
Medication related factors 
No. of unique medications filled 
Opioid Medication Use 
0 opioid medication filled (Ref) 
1 opioid medication filled 
2-3 opioid medications filled 
>4 opioid medications filled 
Number of unique prescribers 
Number of unique pharmacies 
 
0.93 (0.89-0.96) 
 
 
1.21 (0.85-1.74) 
1.21 (0.83-1.78) 
1.57 (0.94-2.08) 
1.09 (1.03-1.16) 
1.08 (0.95-1.21) 
 
<0.001 
 
 
0.288 
0.326 
0.101 
0.005 
0.235 
Health care utilization 
>1 physician office visits  
 
0.66 (0.45-0.98) 
 
0.037 
 
Significant at P<0.05. The model included lagged effects of comorbidity, therapy 
complexity-related, and health care utilization factors.  
*Mental illness was defined as >1 antidepressants or anxiolytics fill or diagnosis of 
depression/anxiety. 
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Table A-4. Multivariate Associations with Medication Nonadherence Using 
Alternative PDC Criteria of ≥1 Medication Fill (N=3,062 Patient-Periods) 
 
 Nonadherence 
Characteristics Odds Ratio (95% CI) P Value 
<65 years 1.61 (1.23-2.10) <0.001 
Female 1.16 (0.90-1.49) 0.242 
Non-Hispanic black 1.03 (0.78-1.37) 0.830 
Non-dual LIS 
Dual LIS 
1.43 (0.95-2.17) 
1.46 (1.08-1.98) 
0.089 
0.014 
Comorbidity 
Charlson comorbidity index  
Diagnosis of tobacco abuse disorder  
Mental illness 
 
1.00 (0.96-1.04) 
0.96 (0.69-1.34) 
0.76 (0.59-0.99) 
 
0.905 
0.828 
0.040 
Medication related factors 
Unique other medications filled 
Opioid Medication Use 
0 opioid medication filled (Ref) 
1 opioid medication filled 
2-3 opioid medications filled 
>4 opioid medications filled 
Unique prescribers 
Unique pharmacies 
 
0.96 (0.94-0.99) 
 
 
1.23 (0.91-1.67) 
1.17 (0.85-1.60) 
1.62 (1.19-2.20) 
1.09 (1.04-1.15) 
1.04 (0.95-1.15) 
 
0.003 
 
 
0.177 
0.344 
0.002 
<0.001 
0.363 
Health care utilization 
>1 physician office visits  
 
0.60 (0.45-0.82) 
 
0.001 
 
Significant at P<0.05. The model included lagged effects of comorbidity, therapy 
complexity-related, and health care utilization factors. 
*Mental illness was defined as >1 antidepressants or anxiolytics fill or diagnosis of 
depression/anxiety.  
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APPENDIX B. SUPPLEMENTAL MATERIALS FOR CHAPTER 3  
 
 
Table B-1. Multivariable Results for Inpatient Stays and ED Visits Among 
Medicare Beneficiaries ≥65 years Using Random Effects Models (N=1,757 patient-
periods) 
 
 Inpatient Stays    ED Visits 
Characteristics IRR (95% CI) P Value  IRR (95% CI) P Value 
Overall medication nonadherence 1.37 (1.23-1.52) <0.001  1.20 (1.04-1.39) 0.016 
Female 0.98 (0.88-1.09) 0.691  1.04 (0.87-1.25) 0.660 
Non-Hispanic Black 0.90 (0.79-1.01) 0.083  1.40 (1.14-1.71) 0.001 
Non-Dual LICS 
Dual LICS 
1.17 (0.96-1.42) 
1.13 (1.00-1.28) 
0.120 
0.045 
 1.31 (0.96-1.79) 
1.44 (1.18-1.75) 
0.093 
<0.001 
Comorbidity 
Charlson comorbidity index 
Mental illness 
Tobacco abuse disorder  
 
1.08 (1.06-1.09) 
1.16 (1.03-1.30) 
1.14 (0.99-1.32) 
 
<0.001 
0.015 
0.065 
  
1.06 (1.03-1.09) 
1.47 (1.24-1.75) 
1.03 (0.82-1.29) 
 
<0.001 
<0.001 
0.818 
Opioid medication filled 
0 opioid fill (ref) 
1 opioid fill 
2-3 opioid fill 
>3 opioid fill 
Number of unique medications 
filled 
 
 
1.02 (0.88-1.18) 
0.92 (0.78-1.08) 
0.92 (0.80-1.06) 
1.01 (1.00-1.03) 
 
 
0.830 
0.331 
0.263 
0.118 
 
  
 
1.05 (0.85-1.29) 
1.08 (0.87-1.34) 
0.95 (0.77-1.19) 
0.98 (0.95-1.00) 
 
 
0.661 
0.495 
0.670 
0.047 
Number of unique prescribers 1.01 (0.98-1.03) 0.697  1.07 (1.03-1.11) <0.001 
>1 physician office visits  0.91 (0.78-1.05) 0.192  4.06 (2.87-5.74) <0.001 
 
Significant at P<0.05. IRR: Incidence Rate Ratio. ED visits: Emergency department 
visits. 
We used random effects negative binomial models at patient level. The models included 
lagged effects of all the above factors.  
Overall medication nonadherence measured at patient-level was based on seventeen 
index drug classes. 
Mental illness is defined as >1 antidepressants or anxiolytics fill or diagnosis of 
depression/anxiety.  
The multivariable model with inpatient stays as outcome included 1,227 patient-periods. 
The multivariable model with ED visits as outcome included 986 patient-period.
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Table B-2. Multivariable Results for Inpatient Stays and ED Visits Among 
Medicare Beneficiaries <65 years Using Random Effects Models (N=1,242 patient-
periods) 
 
 Inpatient Stays    ED Visits 
Characteristics IRR (95% CI) P Value  IRR (95% CI) P Value 
Overall medication nonadherence 1.37 (1.21-1.54) <0.001  1.32 (1.13-1.54) 0.001 
Female 1.04 (0.93-1.18) 0.489  1.04 (0.85-1.27) 0.723 
Non-Hispanic Black 1.06 (0.91-1.22) 0.459  1.25 (0.98-1.58) 0.072 
Non-Dual LICS 
Dual LICS 
1.15 (0.89-1.49) 
1.07 (0.85-1.34) 
0.294 
0.559 
 1.37 (0.88-2.13) 
1.51 (1.03-2.21) 
0.162 
0.037 
Comorbidity 
Charlson comorbidity index 
Mental illness 
Tobacco abuse disorder  
 
1.08 (1.06-1.09) 
1.15 (1.02-1.31) 
1.28 (1.13-1.44) 
 
<0.001 
0.026 
<0.001 
  
1.06 (1.03-1.09) 
1.26 (1.05-1.53) 
1.30 (1.07-1.58) 
 
<0.001 
0.015 
0.008 
Opioid medication filled 
0 opioid fill (ref) 
1 opioid fill 
2-3 opioid fill 
>3 opioid fill 
Number of unique medications 
filled 
 
 
0.84 (0.69-1.02) 
0.99 (0.83-1.19) 
1.16 (0.99-1.35) 
0.99 (0.98-1.01) 
 
 
0.076 
0.948 
0.064 
0.783 
 
  
 
0.83 (0.64-1.06) 
0.89 (0.70-1.14) 
1.05 (0.83-1.32) 
1.01 (0.99-1.03) 
 
 
0.133 
0.356 
0.694 
0.535 
Number of unique prescribers 1.02 (1.00-1.04) 0.075  1.05 (1.03-1.08) <0.001 
>1 physician office visits  0.80 (0.68-0.95) 0.009  1.82 (1.33-2.49) <0.001 
 
Significant at P<0.05. IRR: Incidence Rate Ratio. ED visits: Emergency department 
visits. 
We used random effects negative binomial models at patient level. The models included 
lagged effects of all the above factors.  
Overall medication nonadherence measured at patient-level was based on seventeen 
index drug classes. 
Mental illness is defined as >1 antidepressants or anxiolytics fill or diagnosis of 
depression/anxiety.  
The multivariable model with inpatient stays as outcome included 1,227 patient-periods. 
The multivariable model with ED visits as outcome included 986 patient-periods.
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Table B-3. Multivariable Results for Inpatient Stays and Emergency Department 
Visits Among Medicare Beneficiaries ≥65 years Using ≥1 Medication Fill Criteria 
 
 Inpatient Stays    ED Visits 
Characteristics IRR (95% CI) P Value  IRR (95% CI) P Value 
Overall medication nonadherence 1.78 (1.50-2.12) <0.001  1.14 (0.94-1.39) 0.192 
Comorbidity 
Charlson comorbidity index 
Mental illness 
Diagnosis of tobacco use 
disorder  
 
1.22 (1.17-1.28) 
1.54 (1.20-1.96) 
1.31 (0.91-1.86) 
 
<0.001 
0.001 
0.145 
  
1.17 (1.10-1.23) 
1.46 (1.11-1.93) 
0.69 (0.45-1.05) 
 
<0.001 
0.006 
0.082 
Opioid medication filled 
0 opioid fill (ref) 
1 opioid fill 
2-3 opioid fill 
>3 opioid fill 
Number of unique medications 
filled 
 
 
0.98 (0.78-1.22) 
0.87 (0.67-1.12) 
0.89 (0.66-1.20) 
1.01 (0.99-1.03) 
 
 
0.846 
0.270 
0.445 
0.461 
 
  
 
0.94 (0.73-1.20) 
0.95 (0.73-1.25) 
0.83 (0.57-1.19) 
0.97 (0.94-1.00) 
 
 
0.611 
0.736 
0.306 
0.099 
Number of unique prescribers 0.97 (0.92-1.02) 0.211  0.98 (0.93-1.04) 0.537 
>1 physician office visit  0.95 (0.70-1.28) 0.721  1.51 (0.94-2.42) 0.086 
 
Significant at P<0.05. IRR: Incidence Rate Ratio. ED visits: Emergency department visits 
We used fixed effects negative binomial models at patient level. The models included 
lagged effects of all the above factors.  
Overall medication nonadherence measured at patient-level was based on seventeen 
index drug classes. 
Mental illness is defined as >1 antidepressants or anxiolytics fill or diagnosis of 
depression/anxiety.  
The multivariable model with inpatient stays as outcome included 1,792 patient-periods. 
The multivariable model with ED visits as outcome included 1,250 patient-periods.
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Table B-4. Multivariable Results for Inpatient Stays and ED Visits Among 
Medicare Beneficiaries <65 years Using ≥ Medication Fill Criteria 
 
 Inpatient Stays    ED Visits 
Characteristics IRR (95% CI) P Value  IRR (95% CI) P Value 
Overall medication nonadherence 1.46 (1.21-1.76) <0.001  1.24 (1.01-1.51) 0.038 
Comorbidity 
Charlson comorbidity index 
Mental illness 
Diagnosis of tobacco use 
disorder  
 
1.18 (1.13-1.23) 
1.20 (0.92-1.56) 
1.72 (1.26-2.34) 
 
<0.001 
0.184 
0.001 
  
1.11 (1.05-1.16) 
1.18 (0.88-1.58) 
1.30 (0.92-1.82) 
 
<0.001 
0.277 
0.135 
Opioid medication filled 
0 opioid fill (ref) 
1 opioid fill 
2-3 opioid fill 
>3 opioid fill 
Number of unique medications 
filled 
 
 
0.82 (0.64-1.06) 
0.87 (0.67-1.14) 
1.03 (0.75-1.43) 
0.99 (0.96-1.01) 
 
 
0.124 
0.309 
0.835 
0.257 
  
 
0.90 (0.69-1.18) 
0.94 (0.71-1.25) 
1.14 (0.81-1.62) 
1.00 (0.98-1.02) 
 
 
0.459 
0.674 
0.452 
0.969 
Number of unique prescribers 1.00 (0.96-1.03) 0.836  0.99 (0.96-1.03) 0.643 
>1 physician office visit  0.84 (0.64-1.10) 0.212  0.87 (0.62-1.22) 0.416 
 
Significant at P<0.05. IRR: Incidence Rate Ratio. ED visits: Emergency department visits 
We used fixed effects negative binomial models at patient level. The models included 
lagged effects of all the above factors.  
Overall medication nonadherence measured at patient-level was based on eighteen index 
drug classes. 
Mental illness is defined as >1 antidepressants or anxiolytics fill or diagnosis of 
depression/anxiety.  
The multivariable model with inpatient stays as outcome included 1,299 patient-periods. 
The multivariable model with ED visits as outcome included 1,045 patient-period. 
 
  
 85 
APPENDIX C. SUPPLEMENTAL MATERIALS FOR CHAPTER 4 
 
 
Table C-1. Key SafeMed Care Transitions Interventions at Different Time Points 
 
Week Activities Lead staff* 
  Hospital-based   
0 Real time in-hospital identification, screening and 
enrollment of eligible patients 
NP/RN 
Introduction of SafeMed team and initial patient 
engagement with team and SafeMed program 
SafeMed team 
Medication reconciliation and medication therapy 
management 
Pharmacist, CPhT-
CHW 
Enhanced discharge preparation, planning, education 
and care coordination with outpatient providers and 
community resources 
NP/RN, Pharmacist 
 Community-based   
1 1st home visit within 72 hours  
of discharge 
x Symptom and physical assessment 
x Medication reconciliation 
x Medication therapy management 
x Identify and address social needs 
  
 
LPN-CHW 
CPhT-CHW 
Pharmacist (remote) 
SW/LPN-CHW 
2 Phone follow-up and care coordination to ensure PCP 
appointment within 14 days of enrollment 
CPhT-CHW and 
LPN-CHW  
3 2nd home visit 
x Symptom and physical assessment 
x Medication reconciliation 
x Medication therapy management 
x Identify and address social needs 
  
LPN-CHW 
CPhT-CHW 
Pharmacist (remote) 
SW/LPN-CHW 
4 30-day phone follow-up CPhT-CHW and 
LPN-CHW  
5 In-clinic comprehensive medication review (30-45 days 
after enrollment) 
Pharmacist (CPhT-
CHW to schedule) 
6 SafeMed support session: monthly peer support group 
and educational session open to all program participants 
on an ongoing basis 
SafeMed team   
 
*The following abbreviations are used for lead SafeMed staff categories: nurse 
practitioner (NP), registered nurse (RN), licensed practical nurse–community health 
worker (LPN-CHW), certified pharmacy technician–community health worker (CPhT-
CHW), social worker (SW). 
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